



# MONASH University

**Polymer modified ion exchange adsorbent  
for the flow-through chromatography of hepatitis B virus-like  
particle**

Ng Hon Wei

(Master of Engineering in Chemical Engineering, University of Nottingham, Malaysia  
Campus)

A thesis submitted for the Master of Engineering Science (Research) at  
Monash University in 2018  
School of Engineering

## **Copyright Notice**

© Ng Hon Wei (2018). As provided in the Copyright Act 1968, this thesis may not be reproduced in any form without the written permission of the author.

## Abstract

Virus-like particles (VLP) have gained attention in recent years due to its potential application in vaccine development, drug encapsulation, and targeted gene delivery. Purification of VLP with bind-and-elute mode ion exchange chromatography encounters setbacks such as low adsorption capacity and disintegration of the VLPs. Size selective flow-through chromatography (FC) can be employed to overcome these problems, where small host cell proteins (HCPs) molecules are adsorbed and the large hepatitis B core antigen virus like particles (HB-VLPs) are recovered in the flow-through fraction. In this study, a poly[oligo(ethylene glycol) methacrylate] (POEGMA) grafted adsorbents were developed to reduce the adsorption of HB-VLPs. The effect of feedstock conditions (size of target protein and protein load) and adsorbent design (adsorbent size, type of polymer chain and POEGMA architecture) on the performance of FC were investigated. The feedstock containing hepatitis B core antigen-Y132 tridimers (HB-tridimers) - a much smaller variant of the HB-VLPs, was employed to evaluate the effect of target protein size on the adsorption capacity of the adsorbent. Breakthrough curves indicated that overall adsorption capacity of adsorbent was significantly reduced with feedstock containing HB-VLPs, likely due to limited diffusivity of HB-VLPs and large HCPs. The suitable range of protein load for the adsorbent was found to be at 5.5-7.0 mg total protein/ml adsorbent (approximately 15% HCPs breakthrough). The design of the adsorbents also significantly affects the adsorption of HB-VLPs. The use of larger Sepharose Q FF significantly increased flow-through recovery (approximately 2 fold) due to a reduction in surface available for adsorption of the HB-VLPs. Grafted POEGMA was shown to be more suitable for HB-VLPs exclusion compared to the grafted charged dextran, indicating that the non-charged, hydrophilic and inert properties of POEGMA was shown to be more suitable to reduce protein adsorption. The effect of POEGMA architecture on HB-VLP adsorption was also evaluated by using monomers with different branch-chain

length. Adsorbent grafted with a middle branch chain length, POEGMA<sub>300</sub> showed a 92% flow-through recovery of HB-VLPs, higher than the unmodified adsorbents which recorded 75.9% of flow-through recovery, as well as a 5% improvement over the short chain POEGMA<sub>200</sub> polymer from a previous study by our research group. The attributes of the polymer modified adsorbents developed shows its potential used to recover HB-VLPs from clarified *E. coli* homogenate.

## **Publications during Enrolment**

1. **H.W. Ng**, M.F.X. Lee, G.K. Chua, B.K. Gan, W.S Tan, C.W. Ooi, S.Y. Tang, E.S. Chan, B.T. Tey, Size-selective purification of hepatitis B virus-like particle in flow-through chromatography: types of ion exchange adsorbent and grafted polymer architecture, *J Sep Sci.* (2018 Feb 9) doi: 10.1002/jssc.201700823.

## **Collaborations**

1. S.L. Lim, **H.W. Ng**, M.A. Akwiditya, C.W. Ooi, E.S. Chan, Kok Lian Ho, W.S. Tan, G.K. Chua, B.T. Tey, Single-step purification of recombinant hepatitis B core antigen Y132A dimer from clarified *Escherichia coli* feedstock using a packed bed anion exchange chromatography. *Process Biochem.* (2018 March 8.) In Press- Corrected Proof. Doi: 10.1016/j.procbio.2018.03.003

## **Declaration**

This thesis contains no material which has been accepted for the award of any other degree or diploma at any university or equivalent institution and that, to the best of my knowledge and belief, this thesis contains no material previously published or written by another person, except where due reference is made in the text of the thesis.



---

(Ng Hon Wei)

April 2018

## **Acknowledgement**

First and foremost, I wish to express my gratitude to my supervisors, Prof. Beng Ti Tey, Dr Edward Chien Wei Ooi, Dr Patrick Siah Ying Tang and Dr Gek Kee Chua. The support I received throughout was instrumental to the completion of my study. I would also like to thank Prof. Wen Siang Tan and Dr Kok Lian Ho from Universiti Putra Malaysia for providing invaluable advices.

The study was also completed with much needed team support. I appreciate the support and advice from my labmates: Micky Lee, Christine Chiew, Kiang Wei Ho, Hui Peng Lim, Swee Lu Lim, Poay Ling Beh.

Financial support under HDR Scholarship from School of Engineering, Monash University Malaysia is very much appreciated. This study was funded by e-Science grant (06-02-10-SF0255) from the Ministry of Science, Technology and Innovation, Malaysia.

## List of Tables

| Table |  | Page |
|-------|--|------|
| 1     | Methods of purification for HB-VLPs expressed in <i>E. coli</i>  | 14   |
| 2     | Modified adsorbents and their respective polymerization conditions.<br>Reaction performed under nitrogen at 60°C for 3 h with ammonium persulfate as the initiator | 43   |
| 3     | Ionic capacity of adsorbents and the TGA results of modified adsorbents with respect to its unmodified controls  | 47   |

## List of Figures

| Figure |  | Page |
|--------|--|------|
| 1      | Schematic diagram of (a) flow-through chromatography (FC) of <i>E. coli</i> homogenate containing HB-VLPs and (b) mechanism of POEGMA chain excluding HB-VLPs from adsorbent surface   | 3    |
| 2      | Free radical initiated polymerization of POEGMA on anion exchange adsorbents   | 22   |
| 3      | (a) Flow-through protein concentration ratio, $C/C_0$ with at increasing protein load with respect to the feedstock. SDS-PAGE fractions collected from (b) <i>E. coli</i> homogenate containing HB-VLPs and (c) <i>E. coli</i> homogenate containing HB-tridimers                        | 28   |
| 4      | Breakthrough curves for VLPs from <i>E. coli</i> homogenate containing HB-VLPs using POEGMA grafted adsorbent  | 31   |
| 5      | Protein size distribution of the following: (a) flowthrough fraction of (—) QFF-C, and (---) QFF-P200 after FC of <i>E. coli</i> homogenate containing HB-VLPs, (====) <i>E. coli</i> homogenate containing HB-VLPs and (.....) SEC-purified HB-VLPs while (b) flowthrough fraction of ( | 33   |

|    |   |    |
|----|---|----|
|    | <p>——) QFF-C, and ( ■■■) QFF-P200 after FC of <i>E. coli</i> homogenate containing HB-tridimers and ( ·····) <i>E. coli</i> homogenate containing HB-tridimers</p>  |    |
| 6  | Protein collected in the flow-through fraction of (a) <i>E. coli</i> homogenate containing HB-VLPs and (b) <i>E. coli</i> homogenate containing HB-tridimers  | 34 |
| 7  | Confocal laser scanning microscopy (CLSM) of FITC-labelled HB-tridimer on (a) ungrafted QFF-C, (b) polymer grafted QFF-P200; FITC-labelled HB-VLPs on (c) ungrafted QFF-C, (d) polymer grafted QFF-P200 after batch adsorption  | 35 |
| 8  | (a) MrN-VLPs and its HCPs collected in the flow-through fraction and (b) SDS-page results with Lane 1, <i>E. coli</i> homogenate containing MrN-VLPs; Lane 2, flow-through pool of QFF-C; Lane 3, flow-through pool of POEGMA grafted Sepharose QFF (QFF-P200)  | 37 |
| 9  | FTIR spectra of the following adsorbents: (——) QFF-C, ( - · · ) QFF-P200, ( - - - ) QFF-P300, ( ····· ) QFF-P500, ( ——— ) QXL-C, ( - · · · ) QXL-P200, ( - · - ) QHP-C, ( — ) QHP-P200.   | 46 |
| 10 | (a) Chromatograms of SEC-purified HB-VLP feedstock using adsorbents with different size: QHP-C (35 μm) and QFF-C (90 μm), with QHP-P200 and QFF-P200 representing the respective adsorbent grafted with POEGMA <sub>200</sub> . Absorbance (mAU) for ( —— ) QHP-C, ( - · - ) QHP-P200, ( —— ) QFF-C, and ( - · · ) QFF-P200; and ( - - - ) conductivity (mS/cm) against volume of buffer (ml) flowed in the column. (b) Flow-through recovery and PF of HB-VLP from <i>E. coli</i> homogenate | 49 |
| 11 | Size distribution in terms of volume based distribution of proteins collected in the a) flow-through fractions, and b) eluted fractions of adsorbents ( —— ) QHP-C, ( ■■■) QHP-P200, ( —— ) QFF-C, and ( ■■■ ) QFF-P200, and c) ( —— ) <i>E. coli</i> feedstock and ( ····· ) SEC-purified HB-VLPs.   | 52 |
| 12 | Flow-through recovery and PF of HB-VLP from <i>E. coli</i> homogenate using standard adsorbents QFF-C, adsorbents grafted with POEGMA <sub>200</sub>  | 54 |

- (QFF-P200), Sepharose XL adsorbents (QXL-C) and POEGMA grafted QXL-P200
- 13 Illustration of size-selective exclusion of the HB-VLPs and the larger HCPs from the external surface of adsorbents. The smaller HCPs are able to approach the external surface and pores in the adsorbent. (a) Adsorption of HB-VLPs on the additional binding sites of grafts on the unmodified Sepharose XL adsorbent (QXL-C); the dense POEGMA<sub>200</sub> grafts on QXL-P200 adsorbent reduced the diffusion of HCPs to external surface of the adsorbent, and (b) Sepharose Q grafted with POEGMA of increasing side chain length increased the exclusion of larger HCPs and HB-VLPs 56
- 14 (a) Flow-through recovery and PF of FC of HB-VLPs from *E. coli* homogenate and (b) SDS-PAGE results of the feed and flow-through fractions collected. Lanes 1, 2, 3 and 4 represents the fractions purified with QFF-C, QFF-P200, QFF-P300 and QFF-P500 respectively, while (a) represents the first half of flow-through fraction collected and (b) represents the second half of flow-through fraction collected. 57

## Abbreviations

|                                 |   |
|---------------------------------|---|
| APS                             | Ammonium persulfate                                     |
| ATR-FTIR                        | Attenuated total reflectance Fourier transform infrared |
| BSA                             | Bovine serum albumin                                    |
| CLSM                            | Confocal laser scanning microscopy                      |
| CV                              | Column volume   |
| DEAE                            | Diethylaminoethyl                                       |
| DNA                             | Deoxyribonucleic acid                                   |
| DTT                             | DL-Dithiothreitol                                       |
| <i>E. coli</i>                  | <i>Escherichia coli</i>                                 |
| FITC                            | Fluorescein isothiocyanate                              |
| HBcAg                           | Hepatitis B core antigen                                |
| HBV                             | Hepatitis B virus                                       |
| HB-VLP                          | Hepatitis B VLP   |
| HCPs                            | Host cell proteins                                      |
| IgG                             | Immunoglobulin  |
| IMAC                            | Immobilized metal affinity chromatography               |
| IPTG                            | Isopropyl- $\beta$ -D-thiogalactopyranoside             |
| LB                              | Luria Bertani broth                                     |
| LCST                            | Lower critical solution temperature                     |
| MEO <sub>2</sub> MA             | 2-diethylene glycol methacrylate                        |
| M <sub>n</sub>                  | Average molecular weight                                |
| NaHCO <sub>3</sub>              | Sodium bicarbonate                                      |
| Na <sub>2</sub> CO <sub>3</sub> | Sodium carbonate  |

|                      |  |
|----------------------|--|
| OEG                  | Oligo(ethylene glycol)   |
| OEGMA                | oligo(ethylene glycol) methacrylate  |
| OEGMA <sub>300</sub> | Poly[oligo(ethylene glycol) methyl ether methacrylate] $M_n = 300\text{g/mol}$ |
| OEGMA <sub>500</sub> | Poly[oligo(ethylene glycol) methyl ether methacrylate] $M_n = 500\text{g/mol}$ |
| PEG                  | Polyethylene glycol  |
| PEO                  | Polyethylene oxide   |
| PF                   | Purification factor  |
| pI                   | Isoelectric point  |
| POEGMA               | Poly[oligo(ethylene glycol) methacrylate]                                      |
| SDS-PAGE             | Sodium dodecyl sulfate polyacrylamide gel electrophoresis                      |
| SEC                  | Size exclusion chromatography  |
| TEM                  | Transmission electron microscopy   |
| Tris                 | Tris(hydroxymethyl)aminomethane  |
| VLP                  | Virus-like particle  |

# Table of Contents

|   |      |
|---|------|
| Copyright Notice  | ii   |
| Abstract  | iii  |
| Publications during Enrolment   | v    |
| Declaration   | vi   |
| Acknowledgement   | vii  |
| List of Tables  | viii |
| List of Figures   | viii |
| Abbreviations   | xi   |
| Table of Contents   | xiii |
| Chapter 1: Introduction   | 1    |
| 1.1. Aims   | 4    |
| Chapter 2: Literature Review  | 5    |
| 2.1. Virus-like-particles (VLPs)  | 5    |
| 2.2. Purification of VLPs   | 6    |
| 2.3. Flow-through mode ion exchange chromatography  | 7    |
| 2.4. Size exclusion layer on chromatography adsorbents  | 10   |
| 2.5. Inert polymer modification for protein adsorption reduction  | 12   |
| 2.6. Purification of HB-VLP expressed in <i>E. coli</i>   | 13   |
| 2.7. Concluding remarks   | 16   |
| Chapter 3: Size selective flow-through chromatography purification of hepatitis B virus-like particle: effect of protein load and target protein size | 17   |
| 3.1. Introduction   | 17   |
| 3.2. Materials and Method   | 19   |
| 3.2.1. Chemicals and materials  | 19   |
| 3.2.2. Preparation of clarified <i>E. coli</i> homogenate containing HB-VLPs, HB-tridimers or MrN-VLPs  | 20   |
|   | xiii |

|  |    |
|--|----|
| 3.2.3. Preparation of clarified <i>E. coli</i> homogenate containing Noda-virus-like particles   | 21 |
| 3.2.4. Free radical polymerization grafting of POEGMA on anion exchange adsorbents   | 21 |
| 3.2.5. Chromatography of <i>E. coli</i> homogenate containing HB-VLPs, HB-tridimers or MrN-VLPs  | 22 |
| 3.2.6. Protein quantitation and protein size distribution  | 23 |
| 3.2.7. Determination of protein size distribution  | 24 |
| 3.2.8. Confocal laser scanning microscopy (CLSM)   | 24 |
| 3.2.9. Calculations  | 25 |
| 3.3. Results and Discussion  | 27 |
| 3.3.1. Breakthrough curves from <i>E. coli</i> homogenates containing HB-VLPs and HB-tridimers   | 27 |
| 3.3.2. Optimum protein load for FC using POEGMA grafted adsorbent  | 30 |
| 3.3.3. Chromatography of <i>E. coli</i> homogenate containing HB-VLPs or HB-tridimers  | 32 |
| 3.3.4. Effect of protein size on adsorption of HB-VLPs and HB-tridimers under batch condition  | 34 |
| 3.3.5. Applicability of grafted POEGMA on exclusion of MrN-VLPs  | 36 |
| 3.4. Conclusion  | 38 |
| Chapter 4: Size-selective purification of hepatitis B virus-like particle in flow-through chromatography: types of ion exchange adsorbent and grafted polymer architecture | 39 |
| 4.1. Introduction  | 39 |
| 4.2. Materials and Methods   | 41 |
| 4.2.1. Chemicals and materials   | 41 |
| 4.2.2. Preparation of clarified <i>E. coli</i> homogenate containing HB-VLPs   | 41 |
| 4.2.3. Preparation of HB-VLPs purified with size exclusion chromatography (SEC)  | 42 |
| 4.2.4. Instruments and apparatus   | 42 |

|  |    |
|--|----|
| 4.2.5. Grafting of POEGMA on anion exchange adsorbents   | 43 |
| 4.2.6. Characterization of POEGMA-grafted adsorbent  | 44 |
| 4.2.7. Flow-through chromatography of <i>E. coli</i> homogenate and chromatography of SEC-purified HB-VLPs | 45 |
| 4.2.8. Quantification of protein   | 45 |
| 4.3. Results and Discussion  | 46 |
| 4.3.1. Characterization of adsorbents  | 46 |
| 4.3.2. Effect of adsorbent size on HB-VLPs adsorption  | 47 |
| 4.3.3. Comparison between charged dextran grafts and POEGMA grafts for FC                                  | 53 |
| 4.3.4. Effect of the branch chain length of grafted POEGMA   | 55 |
| 4.4. Conclusion  | 58 |
| Chapter 5: General Discussion, Conclusion and Recommendation for the Future Work                           | 60 |
| 5.1. General discussion  | 60 |
| 5.2. Conclusion  | 61 |
| 5.3. Recommendations for future work   | 61 |
| References   | 63 |

# 1 Chapter 1: Introduction

2 Virus-like particles (VLPs) are non-infectious viral structural protein that resembles  
3 viruses. These highly antigenic VLPs hold promising application in vaccine development,  
4 targeted drug and gene delivery [1]. With recent improvements in upstream processes that  
5 increase yields and harvest volumes, downstream processing (DSP) is becoming increasingly  
6 important in shaping higher overall productivity and lower cost [2].

7 The separation of VLPs from its HCPs can be performed based on differences in size,  
8 charge, or a combination of both [3]. Size exclusion chromatography (SEC) is a direct way of  
9 purifying HB-VLPs, but its low productivity and scalability due to long run-time, low recovery,  
10 product dilution and low capacity makes it undesirable for large scale process. Thus, SEC is  
11 primarily used as an analytical tool while separations based on electrostatic interactions by ion  
12 exchange chromatography (IEC) are usually preferred for preparative separation [4].


13 Generally, the size of VLPs ranges from 22 to 200 nm in diameter, as they are self-  
14 assembled from multiple subunits or monomer [5]. However, the pore size of an agarose-based  
15 adsorbent is approximately 50 nm [6]. The large size of VLPs assembled from hepatitis B core  
16 antigen (HBcAg) has been shown to reduce the intraparticle diffusion in porous ion exchange  
17 adsorbent during bind-and-elute chromatography, which in turn affects its adsorption and  
18 recovery [7]. Negative impacts in terms of slower adsorption kinetics [8] and disassembly (i.e.  
19 disintegration) of multi-subunits structure of the VLP [5] have been well documented. Thus,  
20 flow-through chromatography (FC) where contaminants are adsorbed while VLPs are collected  
21 in flow-through is a viable alternative to bind-and-elute mode chromatography [2]. Since VLPs  
22 can still be adsorbed on adsorbent's external surface [9], polymer modified FC adsorbent has  
23 been used to reduce the HB-VLPs adsorption in order to improve the separation HB-VLPs  
24 from its HCPs.

25 FC is more commonly used for polishing step whereby purified protein samples are  
26 polished by removing low amount of impurities that are closely related to the target protein  
27 [10,11]. In contrast, the application of FC in primary isolation step involving the separation of  
28 the target protein from large quantity of HCPs. Thus the process requires adsorbent with the  
29 capacity to remove large amount of impurities. In other words, the low throughput of FC will  
30 be the main hurdle limiting its application as primary isolation step at preparative scale.

31 Furthermore, most reported studies of FC were aimed at the exclusion of viruses with  
32 hydrodynamic diameter ( $D_H$ ) in the 70-100 nm range [12], which are larger than the pores of  
33 standard adsorbents [approximately (50-70 nm)]. Hence, the separation of smaller HB-VLP  
34 (~32 to 36 nm) from its HCPs [13] will be more challenging to the conventional diffusive  
35 adsorbent. As HB-VLPs are smaller than the average pore size of adsorbents, POEGMA-grafts  
36 were needed to selectively exclude HB-VLPs and to reduce the undesirable adsorption of HB-  
37 VLPs on the surface of the adsorbents.

38 In previous study, FC purification of HB-VLPs from *E. coli* homogenate with a  
39 standard size Sepharose Q FF adsorbent grafted with inert polymer poly(ethylene glycol)  
40 methacrylate (POEGMA) was successfully implemented. A satisfactory HB-VLPs recovery (  
41 >80%) and 2 mg HCPs removed/ml of adsorbent have been achieved [14]. Even though the  
42 adsorbents were successfully employed in primary isolation step chromatography, the FC  
43 performance and the adsorption of HB-VLPs of the adsorbent was not evaluated at different  
44 protein load.

45 Therefore, the main objective of this study was to develop a FC adsorbent with size  
46 selective adsorption properties for the purification of HB-VLP from *E. coli* homogenate. As  
47 depicted in Figure 1, the grafted POEGMA on the adsorbents reduces the mass diffusion and  
48 adsorption of the HB-VLPs while maintaining the adsorption of the smaller size HCPs.



49

50 **Figure 1.** Schematic diagram of (a) flow-through chromatography (FC) of *E. coli* homogenate  
 51 containing HB-VLPs and (b) mechanism of POEGMA chain excluding HB-VLPs from  
 52 adsorbent surface

53

54 **1.1. Aims**

55 The present study aims to establish POEGMA modified adsorbent as an initial isolation FC  
56 purification process. The investigation was divided into two phases.

57 1. The 1<sup>st</sup> phase - Chapter 3 aims to evaluate the effect of feedstock condition such as  
58 target protein size and protein load on the FC performance. The specific objectives  
59 of this phase are:

- 60 a. To assess the effect of the target protein (HBcAg) size on the adsorption  
61 capacity of adsorbent
- 62 b. To determine the optimum protein load of *E. coli* homogenate with HB-  
63 VLPs using POEGMA grafted adsorbent,
- 64 c. To assess the applicability of POEGMA grafted adsorbents to recover other  
65 VLPs from clarified *E. coli* homogenate.

66 Once the optimal protein load for FC of HB-VLPs are obtained, the design of the grafted  
67 adsorbents are further studied to improve the FC performance

68 2. The 2<sup>nd</sup> phase – Chapter 4 aims to further evaluate the effect of the design of  
69 polymer grafted FC adsorbent on the FC performance. The specific objectives of  
70 this phase are:

- 71 a. To determine the effect of the adsorbent's accessible surface area on FC  
72 performance
- 73 b. To determine the effect of functionality of polymer grafts on FC  
74 performance
- 75 c. To evaluate the effect of POEGMA's ethylene oxide branch chain length on  
76 FC performance

77

## 78 **Chapter 2: Literature Review**

### 79 **2.1. Virus-like-particles (VLPs)**

80 VLPs are empty structural protein of viruses that do not contain any genetic materials.  
81 Therefore, they are non-replicating and non-infectious. To date, over 110 VLPs from more than  
82 35 virus families have been constructed [15]. Some were developed for fundamental research  
83 purposes while most are aimed to be used in vaccines development [16]. VLPs are relatively  
84 safer to use compared to the live or attenuated virus particles as a vital platform for vaccines  
85 development [17]. To date, notable vaccines based on VLP include hepatitis B virus (HBV)  
86 and human papillomavirus (HPV). VLPs have also been widely applied in multivalent vaccine  
87 development to induce humoral and cellular immune responses, and utilized in diagnosis test  
88 to detect a wide range of infectious diseases, among other applications [18].

89 One such VLP is hepatitis B core antigen VLP (HB-VLP), an icosahedral nucleocapsid  
90 assembled from monomers of hepatitis B core antigen (HBcAg). The nucleocapsid structure  
91 consists of 180 or 240 subunits with triangulation number  $T = 3$  or  $T = 4$  [1]. The proper  
92 assembly of HB-VLP is vital for its immunogenicity [19]. The distinctive structure of HB-VLP  
93 can stimulate the body's immune system to secrete antibodies [20], thus HB-VLP has been  
94 successfully employed as a vaccine carrier [21] and as an active component of hepatitis B  
95 vaccine [22].

96

## 97 2.2. Purification of VLPs

98 Advances in upstream processing in recent years have increased recombinant protein  
99 yields, making downstream processing increasingly pivotal in determining overall productivity  
100 and cost of recombinant protein production [2]. Protein purification process aims to separate  
101 the target protein from the impurities. The impurities include process-related impurities such  
102 as reagents and additives (antibiotics and nucleases), or cell substrate impurities such as HCPs,  
103 nucleic acids, and proteoglycans. Whereas product-related impurities include aggregates of  
104 virus and free envelope proteins [23].

105 The separation of VLP from its HCPs can be based on differences in size, charge,  
106 hydrophobicity and affinity [3]. Over the years, the expression level of HB-VLP has increased  
107 from 7% [24] to 30% of total proteins in *E. coli* homogenate [25]. The increased load of  
108 proteins in the feedstock necessitates improved unit operation for higher recovery. Although  
109 size exclusion chromatography (SEC) have been used to separate VLPs from its cell  
110 homogenate with high purity of > 90% [26], these processes have poor scalability due to low  
111 flow rates and low capacity. On the other hand, separations based on electrostatic interactions  
112 by ion exchange chromatography (IEC) are usually preferred for preparative and large scale  
113 applications [23].

114 In general, ion exchange chromatography is a widely applied technique for separation  
115 and purification of large proteins such as VLPs. However, the structure of VLPs is vulnerable  
116 to disintegration during binding and eluting steps, a problem that is especially prevalent with  
117 standard diffusive agarose-based adsorbents. Additionally, the small pore size (approximately  
118 50-70 nm) found in these adsorbent has resulted a slow intraparticle diffusional transport of the  
119 VLPs [27], which in turn causes a significant reduction in VLPs adsorption [7].

120           The challenges with mass diffusion of large proteins in diffusive adsorbents can be  
121 addressed with a new generation of adsorbents. These perfusion adsorbents possess large  
122 micron range pores designed to provide better mass transport to large proteins. This in turn  
123 improves the adsorption of these large proteins [5,8,28]. However, large pores that are more  
124 than 6  $\mu\text{m}$  or 10 times the hydrodynamic radius ( $D_H$ ) were required to obtain satisfactory  
125 recovery for large virus particles [29]. Besides, the stability and correct assembly of VLP  
126 recovered using bind-and-elute mode is another concern [30]. A study by Yu et. al. [11] using  
127 perfusion adsorbent DEAE AP 280nm (approx. 10 times larger than the VLP's  $D_H$ ), reported  
128 a 25% disintegration of the recovered VLPs [5]. These modified adsorbents are also designed  
129 with increased surface area in order to improve accessible of ligands, leading to inherent  
130 drawbacks such as increased impurity binding to the adsorbents [31]. Reducing the ligand  
131 density on ion exchange adsorbents have been shown to be effective in maintaining the  
132 structure of VLP during bind-and-elute process. However, such strategy would necessitate  
133 longer column and in turn causes difficulty in scaling up the process [32].

134

### 135 **2.3. Flow-through mode ion exchange chromatography**

136           The difficulty in recovering VLPs with standard diffusive adsorbents makes flow-  
137 through chromatography (FC) a viable alternative to bind-and-elute mode. In FC, the impurities  
138 are adsorbed while the target protein pass through the column and is recovered in the flow-  
139 through fraction. Generally, FC shortens the processing time, and circumvents other post-  
140 processing (i.e. desalting) of the product [33,34], especially when it is dealing with high protein  
141 load feedstock [35]. In addition, the bioactivity of the product purified with FC is well  
142 preserved with minimal product loss since the VLPs does not have strong interaction with the  
143 adsorbent.

144 Different modes of interaction including ion exchange [11], hydrophobic interaction  
145 [33], and specific interaction such as immune-affinity [36] are used in FC. However, it is  
146 challenging to operate FC using selective ligands such as immune-affinity is dealing with  
147 heterogeneous and complicated mixture of impurities [37–39]. Thus, thorough screenings for  
148 suitable ligand are often necessary.

149 In this study, ion exchange chromatography was used, as this mode of purification is  
150 still the workhorse of the industry. FC has been commonly applied to remove trace impurities  
151 from monoclonal antibody IgG feed streams [40–43]. Viruses [31], enzymes [44], Hb  
152 (haemoglobin) [45] and cell surface proteins [40] have also been polished using FC to remove  
153 the impurities.

154 Purification of IgG using FC has shown to be efficient in human serum albumin (HSA)  
155 removal that has been resulted in an increase in IgG purity from 20% to 90% with a purification  
156 factor 4 - 4.5 [46]. As isoelectric point of HSA is generally in acidic range of pI=4.4 while  
157 IgGs commonly have pI=5.5-8, resulting in a stark difference of adsorptive behaviour between  
158 the two species. This has allowed a high flow-through recovery and PF of the IgG using FC.

159            However, the HB-VLPs and its HCPs possess similar adsorptive behaviour due to  
160 overlapping isoelectric point [47,48], likely causing unwanted adsorption of the target protein  
161 As such, difference of size between target protein and impurities can be used to improve the  
162 separation. Currently, some reported studies of FC were aimed at the exclusion of large viruses,  
163 such as adenovirus (70-100 nm) [12] and influenza virus (80-120 nm) from smaller size HCPs  
164 [31]. However, our research group focuses on the purification of smaller HB-VLP (~32 to 36  
165 nm) that are more challenging to separate from its HCPs [13]. Thus, an additional size  
166 exclusion layer is required to reduce the adsorption of the target HB-VLPs to improve flow-  
167 through recovery.

168

## 169 **2.4. Size exclusion layer on chromatography adsorbents**

170 One straightforward method to reduce undesired adsorption of target VLPs in FC can  
171 be achieved by using larger adsorbent. Larger adsorbent possesses lower external surface area  
172 to volume ratio (eSA:V) that in turn reduce the target virus's interaction with ligand [31].  
173 However, the adsorption capacity of HCPs for large adsorbent is low, hence, a poor resolution  
174 or purification factor of VLP is expected.

175 Alternatively, size selective inert layer can be employed in FC adsorbent design. Size  
176 selective FC adsorbents coated with inert layer were developed primarily for analytical scale  
177 separations, method otherwise known as restricted access media (RAM) analysis. Protein-  
178 coated porous silica was used to remove small molecules for drug analysis in plasma [49];  
179 setting the foundation for new methods to separate smaller proteins [50–52]. RAM concept  
180 was also employed in developing adsorbents made from silica supports with an hydrophilic  
181 polymer (silicone) coating acting as a semi-permeable layer [53]. Similarly, RAM with strong  
182 cationic group was employed to identify heroin metabolites in human urine [54]. Adsorbents  
183 with well-defined molecular weight cut-off have been used, one example is the mesoporous  
184 silica adsorbent with narrow pore size distribution. The adsorbent successfully produced sharp  
185 extractions of peptides from human plasma [55] and separation of serum phosphopeptides [56].

186 Since common adsorbents do not possess narrow pore size distribution, modification  
187 with a semi-permeable inert layer on adsorbent can be effective in reducing unwanted  
188 adsorption of large proteins. Ion exchange adsorbents such as Sepharose DEAE FF or  
189 Streamline DEAE have been modified with inert agarose outer shell to exclude large nano-  
190 particles of bovine serum albumin, resulting in up to 10-fold increase in flow-through recovery  
191 [57,58]. Ion exchange adsorbent had also been modified with hydroalkyl-group based neutral  
192 coating to exclude plasmid molecules [59].

193           The inert layer coated on the surface adsorbent can be modified to different molecular  
194 weight cut-off point. For instance, CaptoCore™ 700 has a molecular weight cut-off point of  
195 700 kDa compared to Q Sepharose HP that has a molecular weight cut-off point of 4000 kDa.  
196 [60,61]. CaptoCore™ 700 has been used to remove trace impurities from adenovirus in the  
197 polishing step [62] and to remove HCPs and DNA from influenza A and B viruses in FC [10].  
198 However, a core shell adsorbent similar to CaptoCore™ 700, Inert layer 1000, was reported to  
199 result in significant entrapment and product loss when challenged with *E. coli* homogenate  
200 containing HB-VLPs [63]. Diffusional resistance by the inert layer of core shell model has also  
201 been reported to limit the access of proteins (impurities) to the internal binding surface of the  
202 adsorbents, and hence reduce the adsorption rate of impurities [31]. The lower adsorption rate  
203 of impurities has resulted a long adsorption time or long column length that limits its  
204 applicability on large and preparative scale.

205

## 206 **2.5. Inert polymer modification for protein adsorption reduction**

207           Modification of ion exchange adsorbents with inert polymer can reduce adsorption of  
208 HB-VLPs and in turn improve its flow-through recovery [63,64]. The concept of grafting  
209 ethylene oxide based polymer to reduce adsorption of protein is based on poly(ethylene oxide)  
210 (PEO) polymer layer well known ability to suppress protein adsorption on modified/grafted surface  
211 [68]. The hydrophilicity of polymer and the steric hindrance of polymer layer exerted on the  
212 approaching protein are believe to be the mechanism that suppress the protein adsorption [65].  
213 Beside PEO, there are a number of other promising antifouling polymers, namely zwitterionic  
214 polymers, poly(hydroxyl functional acrylates), poly(2-oxazoline)s, poly(vinylpyrrolidone),  
215 and poly(glycerol) [66]. However, PEO is still the most widely used polymer for reducing  
216 protein adsorption and it is inert to most charged proteins [66]. The ability of the grafted PEO  
217 layer to reduce protein adsorption is based on the steric repulsion that decreases the direct  
218 contact between proteins and the underlying surface and the hydration shells which limits the  
219 secondary adsorption of proteins onto the polymer itself [67]. Another proposed mechanism  
220 involves electrostatic charging effect due to the well-ordered monolayers of oligo(ethylene  
221 glycol) [68].

222 Key characteristic of grafted polymer such as grafting density, chain length and  
223 architecture, depend on the polymerisation technique. The key factor affecting protein  
224 resistance is grafting density; even with short chain length, grafted PEO could still resist the  
225 adsorption of protein provided that the surface has a sufficient polymer coverage [69]. Densely  
226 grafted POEGMA brushes have been shown to produce excellent anti-fouling surfaces that  
227 resist protein adsorptions [70]. The effect of hydrophilicity of the polymer was found to be less  
228 significant compared to the surface density of polymer [71]. Thus, densely grafted polymer can  
229 negatively impact the impurities clearance of the adsorbent, as polymer density should be  
230 sufficiently low for HCPs to penetrate while excluding target protein (i.e. the large HB-VLPs).  
231 Since low grafting density have been shown to sufficiently exclude much smaller bovine serum  
232 albumin (BSA) [72], conventional free polymer radicalisation was used by our research group  
233 to graft POEGMA on ion exchange adsorbents [64] as the method has been shown to improve  
234 the size-selective properties of polystyrene latex beads used for size exclusion chromatography  
235 [73].

236 Finally, the resistance to protein adsorption by the grafted polymer is also dependent  
237 on its architecture [74]. For example, the POEGMA with ethylene oxide branch chain have  
238 been shown to be more effective than linear chain PEG [70]. Hence, the effect of polymer  
239 architecture in size selective exclusion of HB-VLPs requires further study.

240

## 241 **2.6. Purification of HB-VLP expressed in *E. coli***

242 Small scale [75] and large scale production of recombinant HB-VLP from *E. coli* have  
243 been successfully carried out, with expression level of HB-VLP at 30% of total proteins in *E.*  
244 *coli* [25]. Purification of HB-VLPs has been performed with different purification techniques  
245 as shown in Table 1.

246 **Table 1.** Methods of purification for HB-VLPs expressed in *E. coli*

| Method of purification  | Recovery (%) | Purity (%) | Purification steps (Time required) | References |
|---|--------------|------------|------------------------------------|------------|
| Sucrose gradient ultracentrifugation <sup>*a</sup>  | 30           | 93         | >3 steps (48-72 h)                 | [76]       |
| Size exclusion chromatography <sup>*a</sup>   | 30           | 85         | 2 steps (12-15 h)                  | [13,24]    |
| Native agarose gel electrophoresis and electroelution <sup>*a</sup>                       | 40           | 90         | 2 steps (4 h)                      | [13]       |
| Immobilized affinity-expanded adsorption chromatography <sup>*b*c</sup>                   | 56           | 91         | 2 steps (2 h)                      | [77]       |
| Ion exchange expanded bed adsorption chromatography (bind-and-elute mode) <sup>*a*c</sup> | 50.7         | 50         | 2 steps (2 h)                      | [4,78]     |
| M13 Phage immobilised expanding bed adsorption chromatography <sup>*a*c</sup>             | 45           | 44         | 2 steps (6 h)                      | [78]       |
| Ion exchange FC <sup>*a*c</sup>   | 60           | 65         | 3 steps (2 h)                      | [14]       |

247 <sup>\*a</sup> Additional clarification step required (pre-processing of feedstock)

248 <sup>\*b</sup> Additional removal of His-tagged required

249 <sup>\*c</sup> Further polishing step required

250 As shown in Table 1, expanded bed adsorption chromatography offers satisfactory  
 251 recovery, short processing time and the capacity to process large amount of feedstock [4,77–  
 252 79]. However, biomass interactions and aggregations onto adsorbent are limitations commonly  
 253 associated with expanded bed chromatography [80]. Additionally, several key challenges of  
 254 ion exchange expanded bed adsorption chromatography include limited recovery due to steric  
 255 hindrance exerted by the adsorbed cell debris and HB-VLP [77] as well as low intraparticle  
 256 mass diffusion of HB-VLPs in standard porous adsorbent [79].

257           Immobilized metal affinity chromatography (IMAC) utilises a specific metal affinity to  
258 adsorb HB-VLPs, which improves its product purity significantly compared to ion exchange  
259 (Table 1) [77]. However, IMAC requires the target protein to possess a special histidine peptide  
260 tag and it necessitates a post processing step to remove the histidine tag. On the other hand,  
261 purification based on size differences such as size exclusion chromatography can provide high  
262 product purity [24,76]. However, the process is tedious (12-14 hour of run-time), the recovery  
263 is low (20%), and the processing capacity is much lower (0.4 mg of total protein/ ml adsorbents)  
264 compared to ion exchange chromatography (IEC) (1-2 hour run-time, 80-90% recovery and  
265 processing capacity of 10 mg total protein/ml adsorbent).

266           Among the available methods to purify HB-VLPs, ion exchange chromatography is  
267 non-specific. Thus, the effects of polymer grafts can be applicable for separation of other types  
268 of viruses and VLPs from their smaller HCPs. Besides, packed bed chromatography is widely  
269 used and are readily scalable.

270           HB-VLP and its HCPs possess similar adsorptive behaviour – more than 90% of HCPs  
271 are acidic (isoelectric point range = 4.53 – 6.72) [47], which overlaps with the pI of HB-VLP  
272 (pI= 4.0) [48]. Hence, there is a need to use a size selective polymer layer to improve separation  
273 of HB-VLPs from its HCPs [17]. Study of POEGMA grafted adsorbent on expanded bed  
274 chromatography was avoided to reduce unwanted interaction from cell debris.

275           In short, FC enables better preservation of the VLP structure with minimal effect on the  
276 antigenicity. Furthermore, the impurities removal capacity is sufficiently high at 2 mg of  
277 impurities removed/ ml adsorbent [63]. Thus, the focus of this study is to improve the  
278 performance of FC for the purification of HB-VLPs.

279

## 280 **2.7. Concluding remarks**

281           The literature survey presented reveals several research gaps as well as limitations in  
282 the current adsorbent design for FC. One related area that can also be explored is the primary  
283 isolation step for VLPs, especially the selectivity and performance at different protein load.  
284 Investigation would outline the applicability and scalability of diffusive porous adsorbent. As  
285 for the polymer itself, a previous study has demonstrated the effect of longer POEGMA chain  
286 length on the FC performance [64]. However, the architecture of the POEGMA i.e. the ethylene  
287 oxide branch chain was not explored. Hence, the objective of the project was the development  
288 of FC adsorbent for the purification of HB-VLP from *E. coli* clarified lysate, in terms of  
289 purification factor (PF) or recovery of HB-VLP.

290

291 **Chapter 3: Size selective flow-through chromatography**  
292 **purification of hepatitis B virus-like particle: effect of protein load**  
293 **and target protein size**

294

295 **3.1. Introduction**

296 Hepatitis B core antigen (HBcAg) virus-like particles or HB-VLPs are the potential  
297 delivery vehicles for gene and drug [81], as well as the universal carriers of multi-component  
298 vaccines [77]. The large size of HB-VLPs have been reported to significantly reduce its  
299 intraparticle diffusive mass transport in porous ion exchange adsorbents (diffusive adsorbents),  
300 which in turn affects its adsorption [7]. Thus, flow-through chromatography (FC) i.e.,  
301 contaminants adsorbing to the adsorbent and VLPs particles collected in flow-through is a  
302 viable alternative to bind-and-elute mode chromatography [2].

303 However, FC are usually used for polishing step in which the amount of impurities  
304 adsorbed are usually low. For example, conventional diffusive anion exchange adsorbent was  
305 used to adsorb DNA - up to 0.2 mg DNA/ml adsorbent [10], while another study showed  
306 adsorption of 0.005 mg Chinese hamster ovary HCPs/ml of adsorbent [11]. However, to  
307 establish FC as a primary isolation step, the HCPs binding capacity at protein load higher than  
308 the conventional polishing step should be determined.

309           Since clarified homogenate containing VLPs that have low intraparticle mass transport  
310 in standard diffusive adsorbents, the effect of the target protein (HBcAg) size on the HCPs  
311 clearance should be investigated. Two different *E. coli* feedstocks were employed, one  
312 containing HBcAg virus-like-particles (HB-VLPs) which consist of 183 – 240 units of HBcAg  
313 monomers. The other feedstock contains a much smaller variant of HBcAg called HBcAg-  
314 Y132A, that consist of a total of 6 units of HBcAg monomer, in the form of 3 units of dimer  
315 or ‘trimer of dimers structure’ (referred to as HB-tridimer) [82]. Comparison between the two  
316 feedstocks should elucidate the effect of target protein size on the adsorption capacity of the  
317 adsorbent.

318           Besides, partial displacement of proteins by more favourably adsorbed ones due to  
319 competitive binding have been reported [83]. Partial displacement has also been observed by  
320 loading protein beyond anticipated breakthrough [84]. Thus, the effects of the protein load on  
321 the selectivity and performance of FC should also be investigated.

322           In this chapter, analysis of breakthrough curve with *E. coli* homogenate containing HB-  
323 VLPs was performed to determine the optimum range of protein loading for better  
324 chromatography performance. Besides, reduction of HB-VLPs adsorption due to POEGMA  
325 grafted adsorbents under different protein load was evaluated. FC operation with *E. coli*  
326 homogenate containing HB-tridimers was performed to evaluate the effect of the target protein  
327 size on the adsorption of HBcAg and HCP. Chromatography of Noda virus-like particles (MrN-  
328 VLPs) was also performed to demonstrate the applicability of POEGMA’s size selective  
329 exclusion on other VLPs.

330

331

## 332 **3.2. Materials and Method**

### 333 **3.2.1. Chemicals and materials**

334 Anion exchange agarose adsorbents, namely Sepharose Q FF was purchased from GE  
335 Healthcare (Switzerland). Monomers for grafting of POEGMA including di(ethylene glycol)  
336 methyl ether methacrylate (MEO<sub>2</sub>MA), polyethylene glycol methacrylates of M<sub>n</sub>=300  
337 (OEGMA<sub>300</sub>) were sourced from Sigma-Aldrich (Singapore). Prior to the polymerization  
338 reaction, the monomers were purified with a neutral alumina flash chromatography.  
339 Ammonium persulfate (APS) was sourced from Acros Organics (Geel, Belgium). Ready-to-  
340 use Bradford assay dye reagent was purchased from Nacalai Tesque (Japan). SEC-purified HB-  
341 VLPs (90% purity) and HB-tridimers (90% purity) was provided by Department of Pathology,  
342 Faculty of Medicine and Health Sciences, Universiti Putra Malaysia. Both pure protein samples  
343 were stained with FITC Isomer I (Sigma-Aldrich, Singapore). Anhydrous dimethyl sulfoxide  
344 (DMSO), sodium carbonate (Na<sub>2</sub>CO<sub>3</sub>), sodium bicarbonate (NaCO<sub>3</sub>) and ammonium chloride  
345 (NH<sub>4</sub>Cl) were also sourced from Sigma-Aldrich, Singapore.

346

347 **3.2.2. Preparation of clarified *E. coli* homogenate containing HB-VLPs, HB-tridimers or**  
348 **MrN-VLPs**

349 The preparation of clarified *E. coli* homogenate containing HB-VLPs was performed  
350 according to protocol described in Ng et al. [25]. The cells of *E. coli* strain W311OIQ  
351 expressing HB-VLPs, were cultured in Luria Bertani (LB) medium containing 100 µg/mL  
352 ampicillin at 37 °C with a shaking speed of 250 rpm. When the absorbance at 600 nm reached  
353 0.8 – 1.0, expression of HB-VLPs was induced by adding isopropyl β-D-1-  
354 thiogalactopyranoside (IPTG) to a final concentration of 1 mM. The protein expression was  
355 continued for another 16 h at 37 °C. Centrifugation at 3,836 g (Heraeus™ Multifuge™ X1  
356 Centrifuge, Thermo Scientific, USA) for 20 min at 4 °C were used to harvest *E. coli* cells from  
357 the culture broth. The harvested cell pellet was resuspended at 10% w/v in 25 mM of Tris-HCl  
358 buffer, pH 8.0. The cell suspension was disrupted with ultrasonication (Q500 Sonicator, Q  
359 Sonica, United States) at 40% amplitude (20 min with 30 s intervals in between pulses). The  
360 clarified homogenate was obtained by centrifugation at 12,000 g at 4 °C for 20 min, and used  
361 as initial feedstock for subsequent chromatography.

362 Similar to HB-VLPs, the cells of *E. coli* strain W311OIQ with the pR1-11E plasmid,  
363 expressing the truncated HBcAg-Y132A (i.e. HB-tridimers) were cultured and subsequently  
364 harvested. The harvested cell pellet was resuspended in 25 mM of Tris-HCl buffer, pH 8.0, 0.1  
365 mM DL-Dithiothreitol (DTT) to avoid agglomeration of the tridimer structure. The cell  
366 disruption and the subsequent cell lysate calcification including ultrasonication and  
367 centrifugation was performed as described in the paragraph above.

368

### 369 **3.2.3. Preparation of clarified *E. coli* homogenate containing Noda-virus-like particles**


370 Transformant with the recombinant plasmid harboring the sequence of the Noda-virus-  
371 like particles (MrN-VLP) protein was cultured in 50 ml of LB broth containing ampicillin (100  
372  $\mu\text{g/ml}$ ). Incubated at  $37^\circ\text{C}$  and shaking speed of 220 rpm was performed overnight. The culture  
373 was then transferred into LB broth (at 2 % inoculum size) and further incubated at  $37^\circ\text{C}$  at 220  
374 rpm for 2 h until an absorbance at 600 nm of 0.6 to 0.8 was reached. IPTG was then added to  
375 the culture (to a concentration of 1 mM) for induction. Another 4 h of incubation of the culture  
376 was conducted at  $25^\circ\text{C}$  and 220 rpm before harvest. The *E. coli* cells were then pelleted by  
377 centrifugation at 3,750 g for 5 min. Then, 10% (w/v) of cell pellet was resuspended in 25 mM  
378 of Tris-HCl buffer, pH 8.0. The cell disruption and the subsequent cell lysate calcification was  
379 performed as been described in Section 3.2.2.

380

### 381 **3.2.4. Free radical polymerization grafting of POEGMA on anion exchange adsorbents**

382 The grafting of POEGMA polymer onto Q Sepharose FF was performed according to  
383 the steps outlined by Lee et al. [85]. An example of the reaction formula of graft  
384 polymerization and the molecular architecture of POEGMA polymer on QFF-C is depicted in  
385 Figure 2. Briefly, 20 ml of 50% (v/v) ethanol solution containing 10% (w/v) or 2 g of filtered  
386 adsorbents Sepharose Q FF (QFF-C) was purged with nitrogen for 30 min. Next, 2 ml of pre-  
387 purged APS solution (1 M) i.e. 1 mmol APS/g adsorbent was used. Then, the mixture was  
388 equilibrated at  $60^\circ\text{C}$  for 15 min. Under an airtight condition, pre-purged monomer solution  
389 ( $\text{MEO}_2\text{MA}$  and  $\text{OEGMA}_{300}$  at 10:1 mole ratio, total of 2 mmol) was transferred to the mixture.  
390 The mixture was reacted at  $60^\circ\text{C}$  for 3 h. After the reaction, the adsorbents were filtered and  
391 washed with a gradually reduced concentration of ethanol solution (80%, 60%, 40%, and 20%

392 ethanol). Lastly, the adsorbents were washed with a copious amount of deionized water. The  
 393 grafted adsorbent is abbreviated as QFF-P200, while the grafted polymer as POEGMA<sub>200</sub>.



394  
 395 **Figure 2.** Free radical initiated polymerization of POEGMA on anion exchange adsorbents  
 396

397 **3.2.5. Chromatography of *E. coli* homogenate containing HB-VLPs, HB-tridimers or**  
 398 **MrN-VLPs**

399         Chromatography of the clarified *E. coli* homogenate was done with an AKTA Purifier  
 400 10 (GE Healthcare, USA). The chromatogram was recorded at wavelength of 280 nm. The 1.0  
 401 ml columns were purchased from BioToolomics (United Kingdom).

402         For breakthrough curve analysis, the feedstock was continuously loaded with  
 403 Superloop 10 ml (GE Healthcare, USA), 0.25 ml fractions are collected using the fraction  
 404 collector Frac-900 (GE Healthcare, USA) as the loading proceeded. Regeneration of the  
 405 adsorbents were subsequently performed by flowing 20 ml of Buffer B (11 ml; 25 mM Tris-  
 406 HCl; pH 8.0; 1 M NaCl) through the column.

407           While for FC, 5 ml of Buffer A (25 mM Tris-HCl; pH 8.0) was first loaded to the  
408 column for equilibration. Subsequently, 0.5 ml of HB-VLP feedstock (i.e., *E. coli* homogenate,  
409 containing 5.8 mg of total proteins and 35.5 – 37.0% of HB-VLPs) was loaded to the  
410 chromatography column. Then, 2.5 ml of Buffer A was flowed through the column followed  
411 by 0.2 ml of Buffer A to wash off the unbound proteins. Subsequently, an isocratic elution was  
412 performed using Buffer B. The chromatography of *E. coli* homogenate containing HB-  
413 tridimers was performed in the same way, 0.5 ml of *E. coli* homogenate with HB-tridimers  
414 (containing 5.9 mg of total proteins and 37.0% of HB-tridimer) was performed with the same  
415 protocol.

416           For MrN-VLP purification, 0.5 ml of the feedstock (2.1 mg total protein, 7.7% MrN-  
417 VLP) was performed with a similar protocol, on a 0.33 ml chromatography column. 2.5 ml of  
418 Buffer A was flowed through the column after injection followed by 0.2 ml for washing.  
419 Subsequently, an isocratic elution was performed using 6 ml of Buffer B.

420

### 421 **3.2.6. Protein quantitation and protein size distribution**

422           The protein concentration (with respect to mg BSA/ml) was quantified using the  
423 Bradford assay [86]. Briefly, 10 µL of sample solution was added into a microtiter plate well,  
424 followed by 200 µL of ready-to-use Bradford reagent (Bio-Rad). The plate is incubated at room  
425 temperature for 5 mins before measuring the absorbance at 595 nm with Sunrise<sup>TM</sup> microplate  
426 reader (Tecan Ltd., Switzerland).

427           The purity of HB-VLPs was evaluated using sodium dodecyl sulfate-polyacrylamide  
428 gel electrophoresis (SDS-PAGE). Firstly, 2x Laemmli Sample Buffer were added to the sample  
429 at 1:1 ratio, with DTT added to a final concentration of 50 mM. Subsequently, the mixture was  
430 heated at 95°C for 5 min [87]. The resolving gel of 15% w/v acrylamide was electrophoresed  
431 for 60 min at 120 V using Mini-PROTEAN® Tetra cell (Biorad, USA). The gel was then  
432 stained with staining solution containing 2.5 % wt Coomassie Brilliant Blue R-250, and  
433 subsequently destained with a solution containing 10% (v/v) acetic acid and 10% (v/v)  
434 methanol. Gel Doc™ XR+ System (Bio-rad, USA) was used to obtain the images of stained  
435 gels from SDS-PAGE using Image Lab™ software. The purity of HB-VLPs was obtained from  
436 the densitometric analysis of gels. The ratio of the intensity of the HBcAg band (17kDa) to that  
437 of all the protein bands was used as to determine the purity of HB-VLPs, as described in Tey  
438 et al. [75].

439

#### 440 **3.2.7. Determination of protein size distribution**

441           A particle size analyzer (Malvern, model Zetasizer Nano ZS, UK) equipped with He-  
442 Ne laser (633 nm) was used to determine the size distribution of protein samples, with 2 min  
443 equilibration at 25°C in the automatic optimization mode. The total protein concentration of  
444 both feedstocks were adjusted to 1.0 to 1.5 mg/ml, prior to analysis with dynamic light  
445 scattering.

446

#### 447 **3.2.8. Confocal laser scanning microscopy (CLSM)**

448           Confocal laser scanning microscopy (CLSM) was used to evaluate the distribution of  
449 adsorbed HB-VLPs or HB-tridimers within the adsorbent. Pure samples of HB-VLPs and HB-

450 tridimers were fluorescently labelled with FITC Isomer I (Sigma-Aldrich, Singapore)  
451 overnight at 4 °C separately [88]. Excess fluorescent molecules were removed from FITC-  
452 labelled HB-VLPs and HB-tridimers via dialysis for 5 cycles (2 h each) with Buffer A, then  
453 the concentration of FITC-HB-VLPs and FITC-HB-tridimer were adjusted to 1 mg/mL using  
454 Buffer A. For the batch adsorption, 0.1 g of the adsorbent (QFF-C or QFF-P200) was separately  
455 introduced to 5 ml of the above FITC stained protein, and the mixture was incubated for 6 h.  
456 After the adsorption, the adsorbents were washed by Buffer A for four times. CLSM  
457 observation was performed using Nikon Confocal C1 (Nikon, Japan). The laser provided  
458 excitation at 488 nm, with the emitted fluorescent light detected between 500 and 545 nm.  
459 Images were a single confocal scan averaged three times, collected with 1024/1024 resolution  
460 and processed with NIS-Elements C (Nikon, Japan).

461

### 462 3.2.9. Calculations

463 Purity and recovery of target protein were determined using Eq. 3-1 and Eq. 3-2, respectively:

$$464 \text{ Purity} = \frac{\text{Amount of target protein}}{\text{Amount of total protein}} \times 100\% \quad (\text{Eq. 3-1})$$

$$465 \text{ Flow – through recovery (\%)} = \frac{\text{Amount of target protein in flow-through fraction}}{\text{Amount of target protein in feedstock}} \times 100\%$$

$$466 \quad (\text{Eq. 3-2})$$

467 Purification factor (PF) is the ratio of target protein purity in flow-through fraction to the target  
468 protein purity in feedstock:

$$469 \text{ PF} = \frac{\text{Purity of target protein in flow-through fraction}}{\text{Purity of target protein in feedstock}} \quad (\text{Eq. 3-3})$$

470 The total protein loss was defined as the protein not collected in the elution and flow-through  
471 fraction, and was calculated as below:

$$472 \text{ Total protein loss (\%)} = \frac{\text{Amount of total protein in (feed-(flow-through+elution))}}{\text{Amount of Total protein in feed}} \times 100\%$$

473 (Eq. 3- 4)

474

475




## 476 **3.3. Results and Discussion**

### 477 **3.3.1. Breakthrough curves from *E. coli* homogenates containing HB-VLPs and HB-** 478 **tridimers**

479           Analysis of breakthrough curve provides an insight into the interaction between the  
480 target proteins (i.e. HB-VLPs or HB-tridimers) with the adsorbent in comparison to their  
481 respective HCPs. From Figure 3(a), it is apparent that HCPs from *E. coli* homogenate  
482 containing HB-VLPs are preferentially adsorbed, as the concentration ratio in the flow-through,  
483  $C/C_0$  value of HB-VLPs is consistently higher compared to its HCPs. In contrast, the HB-  
484 tridimers were adsorbed preferentially compared to its HCPs. This is an expected trend as the  
485 low intraparticle diffusion of HB-VLPs within the adsorbent causes a markedly lower  
486 adsorption. On the other hand, the smaller HB-tridimers has higher intraparticle diffusion,  
487 hence is able to compete with HCPs for adsorption in the inner sites of adsorbent.

488

489



490

491 **Figure 3.** (a) Flow-through protein concentration ratio,  $C/C_0$  with at increasing protein load  
 492 with respect to the feedstock. SDS-PAGE fractions collected from (b) *E. coli* homogenate  
 493 containing HB-VLPs and (c) *E. coli* homogenate containing HB-tridimers

494           The breakthrough curve in Figure 3(a) obtained for *E. coli* homogenate containing HB-  
495 tridimer is a typical characteristic of porous diffusive adsorbent – 10% breakthrough of the  
496 protein was achieved with relatively low protein load followed by a slow increase in  
497 concentration ratio ( $C/C_0$ ) [84]. In bind-and-elute mode, feedstock are commonly loaded at  
498 10% breakthrough to minimise loss of target protein. The principle can also be applied in FC  
499 mode, where 10% HCPs protein breakthrough can be used as an indication of the impurities  
500 removal capacity of the adsorbent. Thus, protein load at 10% HCPs breakthrough can be used  
501 to indicate a sufficiently high purity product, as most HCPs are adsorbed.

502           As shown in Figure 3(a), 10% HCPs breakthrough was achieved at 5.5 mg total  
503 protein/ml adsorbent for HB-VLPs compared to 13.0 mg total protein/ml adsorbent for HB-  
504 tridimers. Besides, breakthrough curve for HB-VLPs and its HCPs are much steeper compared  
505 to their HB-tridimers counterpart. This was also observed from the SDS-PAGE results in  
506 Figure 3(b), feedstock with HB-VLPs increases drastically and then stabilize at a relatively  
507 constant HB-VLPs purity. In contrast, there is a more gradual increase of HB-tridimers purity  
508 with protein load [Figure 3(c)]. From the comparison of the two feedstocks, it is apparent that  
509 the large HB-VLPs has hindered the adsorption of both HB-VLPs and HCPs onto the adsorbent.  
510 This may be due to the repulsion of HCPs by the HB-VLPs adsorbed on the external surface  
511 of adsorbent [5], as well as convective entrapment of the VLPs within the narrow pores [89].

512 Besides, high protein load did not yield better selective exclusion of the HB-VLPs. As  
513 depicted in Figure 3(a), the difference between  $C/C_0$  value of HB-VLPs and its HCPs was 0.29  
514 at 10% HCPs breakthrough. Beyond that, this value increased and maintained at approximately  
515 0.4, i.e. the adsorbent did not show increasing selectivity beyond 10% HCPs breakthrough. In  
516 contrast, perfusive adsorbents that possess large  $\mu\text{m}$  range pores have shown to exhibit partial  
517 displacement at high protein loading [84]. The partial displacement of weakly adsorbed HB-  
518 VLPs by HCPs in this study were minimal, it is likely that repulsion effect of adsorbed HB-  
519 VLPs prevents diffusion and adsorption of other incoming proteins, that in turn suppresses the  
520 desirable displacement effect.


521 In short, the large size of HB-VLPs was shown to reduce the capacity of the adsorbent  
522 to remove HCPs. In addition, loading up to 7.2 mg total protein/ml adsorbent (15 % HCPs  
523 breakthrough) can be performed without significant offset to the flow-through purity [from  
524 Figure 3 (b)] for standard diffusive adsorbent Sepharose Q FF.

525

### 526 **3.3.2. Optimum protein load for FC using POEGMA grafted adsorbent**

527 Since the  $D_H$  of HB-VLPs at 30 nm [obtained from Transmission Electron Microscopy  
528 (TEM)] [63] is smaller than the adsorbent's pore size (50-70 nm), HB-VLPs may still able to  
529 diffuse into the inner part of the adsorbent. To further improve the flow-through recovery of  
530 HB-VLP, the anion exchange adsorbents were grafted with POEGMA. However, the size  
531 exclusion effect of POEGMA grafts can be affected by the protein load. Therefore, comparison  
532 of the breakthrough curves between grafted and ungrafted adsorbent was performed.

533 At low protein load, more VLPs were excluded by POEGMA grafted QFF-P200  
534 compared to control QFF-C (Figure 4), especially at 5.5-7.0 mg total protein/ml adsorbent. The  
535 competitive binding between different proteins the steric hindrance provided by the grafted  
536 POEGMA, resulting in a modest difference between grafted and ungrafted adsorbent at higher  
537 protein load. Additionally, less HB-VLPs are collected in the flow-through of grafted adsorbent  
538 at higher loading, likely caused by interaction with the POEGMA grafts as the amount of  
539 adsorbed protein accumulates.



540

541 **Figure 4.** Breakthrough curves for VLPs from *E. coli* homogenate containing HB-VLPs using  
542 POEGMA grafted adsorbent

543


544 In short, the applicability of POEGMA modified Sepharose Q-FF are not suited at  
545 higher protein loading. Hence, all further investigation of FC of feedstock containing HB-VLPs  
546 was performed at total protein load of 5.5 mg/ml adsorbent – equivalent to 15% HCPs  
547 breakthrough.

548

### 549 3.3.3. Chromatography of *E. coli* homogenate containing HB-VLPs or HB-tridimers

550 For FC study, the two feedstocks were loaded at approximately 10% HCPs  
551 breakthrough, with *E. coli* homogenate containing HB-VLPs at 5.8 mg total protein/ml  
552 adsorbent, while *E. coli* homogenate containing HB-tridimers at 12.0 mg total protein/ml  
553 adsorbent.

554 From the results of dynamic light scattering shown in Figure 5(a), the collected flow-  
555 through fractions of POEGMA grafted adsorbent contain larger protein compared to the  
556 ungrafted adsorbent. This revealed that the grafted adsorbent was effective at size-selective  
557 exclusion of HB-VLPs from *E. coli* homogenate. The grafted polymer is responsible for  
558 selectively excluding large HB-VLPs from *E. coli* homogenate, with an 10.1% increase of HB-  
559 VLPs flow-through recovery, as shown in the corresponding Figure 6(a). Similarly, for *E. coli*  
560 homogenate containing HB-tridimers, the flow-through fraction of POEGMA grafted  
561 adsorbent also contain larger protein [Figure 5(b)]. However, it was accompanied by an  
562 increase in HCPs - a 28.5% rise compared to QFF-C, as shown in Figure 6(b). This is likely  
563 caused by a fraction of HCPs that was excluded due to its larger size, implying that HCPs size  
564 is not homogenously small. These large HCPs are also excluded with the HB-VLPs, and was  
565 expected to reduce the purity of HB-VLPs in the flow-through.




566

567 **Figure 5.** Protein size distribution of the following: (a) flowthrough fraction of ( — ) QFF-  
 568 C, and ( - - - ) QFF-P200 after FC of *E. coli* homogenate containing HB-VLPs, ( = = = ) *E. coli*  
 569 homogenate containing HB-VLPs and ( ····· ) SEC-purified HB-VLPs while (b) flowthrough  
 570 fraction of ( — ) QFF-C, and ( - - - ) QFF-P200 after FC of *E. coli* homogenate containing  
 571 HB-tridimers and ( ····· ) *E. coli* homogenate containing HB-tridimers

572

573 As shown in Figure 6, a significant difference between the amount of HB-VLPs and HB-  
 574 tridimers collected in the flow-through fraction was observed; with 80% of HB-VLPs collected  
 575 in flow-through while only 10% of HB-tridimers was collected. HCPs removal from feedstock  
 576 with HB-tridimers was also much higher at 4.5 mg HCPs/ml adsorbent while only 1.0-1.6 mg

577 HCPs/ml adsorbent was adsorbed from feedstock with HB-VLPs. The results from FC were  
578 consistent with the results of breakthrough curves using high protein load.



579

580 **Figure 6.** Protein collected in the flow-through fraction of (a) *E. coli* homogenate containing  
581 HB-VLPs and (b) *E. coli* homogenate containing HB-tridimers

582


583 In short, FC results are mostly similar to results from previous section with feedstock  
584 containing HB-VLPs excluded significantly more by the adsorbents compared to HCPs.  
585 Besides, comparison between the two feedstock have shown presence of large HCPs can also  
586 flow-through along with the target HB-VLPs. These large HCPs are likely to be responsible  
587 for a reduced HB-VLPs purity in the product.

588

### 589 3.3.4. Effect of protein size on adsorption of HB-VLPs and HB-tridimers under batch 590 condition

591 CLSM images in Figure 7 show the distribution of FITC-labelled HB-VLPs and FITC-  
592 labelled HB-tridimer on the two anion-exchange adsorbents after 6 h batch adsorption. The  
593 FITC-labelled HB-tridimer can be clearly observed to have diffused into the pores of both

594 adsorbents. Due to its small size, the diffusion of HB-tridimers was not affected by the grafted  
595 POEGMA, resulting in similar distribution between adsorbents shown in Figure 7(a) and  
596 Figure 7(b).



597

598 **Figure 7.** Confocal laser scanning microscopy (CLSM) of FITC-labelled HB-tridimer on (a)  
599 ungrafted QFF-C, (b) polymer grafted QFF-P200; FITC-labelled HB-VLPs on (c) ungrafted  
600 QFF-C, (d) polymer grafted QFF-P200 after batch adsorption

601

602           Conversely, the CLSM results showed that the adsorption of HB-VLPs on both  
603 adsorbents was mostly confined to the external surface of the adsorbents, as diffusion of large  
604 VLPs have been shown to be limited to external surface area on standard diffusive adsorbents  
605 [5]. Nonetheless, from Figure 7(d), POEGMA grafted adsorbent has slightly reduced the  
606 diffusion of HB-VLPs, with a visibly thinner and more confined layer of HB-VLPs on the  
607 external surface of the QFF-P200 adsorbent. Even though batch condition was not a perfect  
608 representation of flow condition of FC, the CLSM results provides qualitative validation of the  
609 FC results, verifying that large HB-VLPs and HCPs have lower adsorption and are confined to  
610 binding sites on the external surface of the adsorbent.

### 611 **3.3.5. Applicability of grafted POEGMA on exclusion of MrN-VLPs**


612           The hydrodynamic radius of MrN-VLPs estimated from TEM is approximately 30 nm  
613 [90], similar to HB-VLPs. The high expression of HB-VLPs from *E. coli* has allowed us to  
614 modify diffusive anion exchange adsorbent for initial isolation step. Unlike HB-VLP,  
615 *Macrobrachium rosenbergii* nodavirus like particles (MrN-VLPs) expressed with *E. coli*  
616 usually results in clarified homogenate of around 7 % purity, as shown in lane 1 (at 51 kDa) of  
617 Figure 7(b). [13]. In contrast, *E. coli* homogenate contained HB-VLPs (35 % purity). The low  
618 purity of *E. coli* homogenate containing MrN-VLPs makes it ill-fitted to be purified using FC.  
619 However, FC of this feedstock allows evaluation of the size selective exclusion of VLPs from  
620 a feedstock with lower VLP purity.

621           QFF-C adsorbent showed a flow-through recovery of 19.0% while QFF-P200 showed  
622 recovery of 33.8 % (a 78.0% increase), as shown in Figure 7(a). The difference of MrN-VLPs  
623 purity obtained in the flow-through fraction is apparent in lane 2 and lane 3 in Figure 7(b). Due  
624 to low VLP purity of the *E. coli* homogenate, the repulsion caused by the VLPs adsorbed on  
625 the external surface of the adsorbent is considerable lower. This in turn results in a more

626 prominent effect by the grafted POEGMA, resulting in a significant increase in VLPs flow-  
627 through recovery.

628 However, the PF was expectedly low (0.63 for QFF-C and 0.90 for QFF-P200), as well  
629 as the flow-through recovery. As FCs are generally tailored for feedstock with higher purity of  
630 VLPs, emphasis should be on the protein load. Nonetheless, further optimisation should be  
631 performed to determine the better flow-through recovery and PF.

632



633

634 **Figure 8.** (a) MrN-VLPs and its HCPs collected in the flow-through fraction and (b) SDS-page  
635 results with Lane 1, *E. coli* homogenate containing MrN-VLPs; Lane 2, flow-through pool of  
636 QFF-C; Lane 3, flow-through pool of POEGMA grafted Sepharose QFF (QFF-P200)

637

### 638 **3.4. Conclusion**

639 From the above results, investigation of protein size effect showed that HB-VLPs  
640 reduced the overall adsorption capacity of the adsorbent. Dynamic light scattering analysis of  
641 flow-through fraction indicate that large HCPs that cannot be adsorbed are likely to be  
642 responsible for limiting higher HB-VLP purity achievable from FC. Compared to other VLPs  
643 from *E. coli* homogenate, *E. coli* homogenate containing HB-VLPs are uniquely suited for  
644 FC at initial isolation step due to its high protein concentration (10 mg total protein/ml) and  
645 VLPs purity (37 % HB-VLPs). In short, the optimum range of protein load of *E. coli*  
646 feedstock containing HB-VLPs has been determined to be around 5.5 – 7.0 mg total  
647 protein/ml adsorbent (15% HCPs breakthrough). Further optimisation on the adsorbent  
648 design will be based on this protein load.

649

650 **Chapter 4: Size-selective purification of hepatitis B virus-like**  
651 **particle in flow-through chromatography: types of ion exchange**  
652 **adsorbent and grafted polymer architecture**

653

654 **4.1. Introduction**

655 In FC of VLPs, the impurities are adsorbed on the adsorbent while the target VLPs are  
656 recovered in the flow-through fractions [85]. This mode of operation circumvents the  
657 shortcomings of bind-and-elute (BE) mode of chromatography, such as the low adsorption  
658 capacity of adsorbents and the risk of VLP disassembly. However, widespread application of  
659 FC for the recovery of VLPs and viruses [10,12,31,91] is still uncommon, mainly due to the  
660 lack of versatile commercial FC adsorbents.

661 Poly[oligo(ethylene glycol) methyl ether methacrylate] (POEGMA) is a type of anti-  
662 fouling polymer. Capitalizing on its ability to resist protein adsorption, our group has developed  
663 POEGMA-grafted ion exchange adsorbents (Sephacrose QFF) for FC of HB-VLPs [64].  
664 Reduction of HB-VLPs adsorption was achieved while adsorption of smaller HCPs  
665 (approximately 5 nm [92]) was held relatively constant when POEGMA grafted adsorbents  
666 were used. The interaction between target protein (i.e., HB-VLPs) and positively charged  
667 quaternary ammonium ligands (Q ligand) have been shown to be modulated by controlling the  
668 chain length of polymer grafted on the adsorbent [64].

669            Nevertheless, the FC recovery of viruses and VLPs could be improved further by  
670 reducing the accessible binding site of the adsorbent. Large anion exchange adsorbent (200  
671  $\mu\text{m}$ ) have been shown to reduce the undesired adsorption of influenza viruses on the external  
672 surface of FC adsorbents [31]. Charged dextran grafts have also shown an improved adsorption  
673 of small HCPs while being restrictive to large biomolecules [93]. Q Sepharose XL, a type of  
674 commercial adsorbent grafted with charged dextran, has been successfully used for the initial  
675 isolation step in FC mode to purify influenza virus [91]. Besides, the size exclusion effect  
676 caused by the POEGMA branch chain was not fully explored. As the length of branch chain of  
677 polymer was known to affect the antifouling properties of modified surfaces [74], it is  
678 postulated that a stronger size exclusion effect could be achieved by optimizing the branch  
679 chain length POEGMA grafts.

680            The 2<sup>nd</sup> phase of the project aimed to further investigate the role of inert POEGMA  
681 graft on the size-selective purification of HB-VLPs by ion exchange adsorbents (i.e., Sepharose  
682 family). Firstly, the effect of adsorbent size (and the accessible binding sites) on the FC  
683 performance was evaluated. Besides, the size exclusion effect of the ethylene oxide branch-  
684 chain length of POEGMA grafts was not fully explored in previous studies [14,63]. It is  
685 postulated that a stronger size exclusion effect could be achieved by optimizing the length of  
686 ethylene oxide branch-chain of POEGMA grafts. Finally, the role of POEGMA grafts in  
687 reducing strong multipoint adsorption and the resulting effect on HB-VLPs assembly were  
688 evaluated. POEGMA grafts and dextran grafts of Q Sepharose XL adsorbents were also  
689 compared to evaluate the effect of functionality of polymer grafts on FC performance.

690

691

## 692 **4.2. Materials and Methods**

### 693 **4.2.1. Chemicals and materials**

694 Anion exchange agarose adsorbents, namely Q Sepharose FF, Q Sepharose XL and Q  
695 Sepharose High Performance, were purchased from GE Healthcare (Switzerland). Monomers  
696 including di(ethylene glycol) methyl ether methacrylate (MEO<sub>2</sub>MA), poly(ethylene glycol)  
697 methacrylates of M<sub>n</sub>=300 (OEGMA<sub>300</sub>) and M<sub>n</sub>=500 (OEGMA<sub>500</sub>) were sourced from Sigma-  
698 Aldrich (Singapore). Prior to the polymerization reaction, the monomers were purified with a  
699 neutral alumina flash chromatography. Ammonium persulfate (APS), silver nitrate (AgNO<sub>3</sub>)  
700 and ammonium sulfate were sourced from Acros Organics (Geel, Belgium). Protein assay  
701 dye reagent concentrate was purchased from Nacalai Tesque (Japan).

702

### 703 **4.2.2. Preparation of clarified *E. coli* homogenate containing HB-VLPs**

704 As outlined in section 3.2.2, *E. coli* homogenate containing HB-VLPs was prepared  
705 from *E. coli* cells (W31101Q strain) and subsequently harvested and clarified.

706

#### 707 **4.2.3. Preparation of HB-VLPs purified with size exclusion chromatography (SEC)**

708 SEC-purified HB-VLPs stock was prepared according to protocol described by Yoon  
709 et al. [13]. Briefly, ammonium sulfate precipitation was performed before size exclusion  
710 chromatography. Ammonium sulfate was added to 35% saturation and stirred at 4°C for 2 h.  
711 The precipitated proteins were recovered by centrifugation at 18,000 g at 4°C for 30 min. The  
712 pellet containing the HBcAg was resuspended in 50mM Tris-HCl, 100 mM NaCl (pH 8) buffer,  
713 and dialyzed against the same buffer with two changes. 2 ml of the processed homogenate was  
714 then purified with size exclusion chromatography (SEC) using Sephacryl-500 adsorbents in a  
715 XK 16/100 column (GE Healthcare) on the Akta Purifier system. The column was equilibrated  
716 with 50 mM Tris-HCl, 100 mM NaCl (pH 8) prior to loading. Proteins were resolved using a  
717 flow rate of 0.5 ml/min and fractions containing HB-VLPs were collected. Purity of HB-VLPs  
718 obtained were 92%. The final concentration of SEC-purified HB-VLPs was adjusted by  
719 dilution with 50mM Tris-HCl, 100 mM NaCl (pH 8) buffer and confirmed with Bradford  
720 Assay.

721

#### 722 **4.2.4. Instruments and apparatus**

723 Eutech Instrument PC700 (USA) was used to measure conductivity of the adsorbent in  
724 adsorbent-water mixture. The functional groups on the polymer grafted agarose beads were  
725 evaluated with an attenuated total reflectance-Fourier transform infrared (ATR-FTIR)  
726 spectrometer (Thermo Scientific, model Nicolet™ iS10 FT-IR, USA). A thermogravimetric  
727 analyzer (TA Instruments, model Q50 TGA, USA) was used to assess the amount of grafted  
728 POEGMA with respect to the unmodified adsorbents. A particle size analyzer (Malvern, model  
729 Zetasizer Nano ZS, UK) equipped with He-Ne laser (633 nm) was used to determine the size  
730 distribution of proteins. The FC of clarified *E. coli* homogenate was performed using a fast

731 protein liquid chromatography system (GE Healthcare, model AKTA Purifier 10, UK). The  
 732 chromatogram was recorded at wavelength 280 nm.

733

#### 734 4.2.5. Grafting of POEGMA on anion exchange adsorbents

735 The free radical graft polymerization of POEGMA polymer on different adsorbents was  
 736 performed according to the steps outlined in Section 3.2.4. However, the pre-purged monomer  
 737 solution (MEO<sub>2</sub>MA, OEGMA<sub>300</sub> or OEGMA<sub>500</sub>) used was shown in Table 2, with the same  
 738 monomer ratio of 2 mmol monomers to 2 g adsorbent. After the reaction, the adsorbents were  
 739 washed with a copious amount of deionized water.

740 **Table 2.** Modified adsorbents and their respective polymerization conditions. Reaction  
 741 performed under nitrogen at 60°C for 3 h with ammonium persulfate as the initiator

| Type of unmodified adsorbent | Abbreviation    | Monomer ratio                                       |
|------------------------------|-----------------|---|
| Q Sepharose FF               | QFF-C (Control) | -   |
|                              | QFF-P200        | 90% MEO <sub>2</sub> MA<br>10% OEGMA <sub>300</sub> |
|                              | QFF-P300        | 100% OEGMA <sub>300</sub>                           |
|                              | QFF-P500        | 100% OEGMA <sub>500</sub>                           |
| Q Sepharose XL               | QXL-C (Control) | -   |
|                              | QXL-P200        | 90% MEO <sub>2</sub> MA<br>10% OEGMA <sub>300</sub> |
| Q Sepharose High Performance | QHP-C (Control) | -   |
|                              | QHP-P200        | 90% MEO <sub>2</sub> MA<br>10% OEGMA <sub>300</sub> |

742

743

#### 744 **4.2.6. Characterization of POEGMA-grafted adsorbent**

745 FTIR spectroscopy was performed to qualitatively confirm the POEGMA grafted on  
746 the adsorbents. To evaluate the amount of POEGMA grafted on adsorbent, thermogravimetric  
747 analysis (TGA) was performed. In brief, the oven-dried adsorbent was heated to 750°C at  
748 10°C/min under nitrogen. The weight losses in adsorbent at 150°C and 700°C were recorded  
749 [85]. The % weight of grafted POEGMA on the modified adsorbent with respect to the  
750 unmodified adsorbent was calculated using Eq. 4-1:

$$751 \text{ \% weight of grafted POEGMA} = (W_{f,c} - W_{f,i}) \times 100\% \quad (\text{Eq. 4-1})$$

752 where  $W_f$  is the final weight fraction of adsorbent at 700°C; the subscripts  $i$  and  $c$  represent the  
753 type of modified adsorbent and its respective control (type of unmodified adsorbent).

754 The ionic capacity of the unmodified adsorbents were characterized by conductometric  
755 titration method according to the protocol used by a previous study [85]. Briefly, 0.01 M of  
756 silver nitrate ( $\text{AgNO}_3$ ) was added to a mixture of 0.1% (w/v) of Q adsorbent with a step size of  
757 0.1 ml. The conductivity of the mixture was measured with Eutech Instrument PC700 (USA)  
758 every 3 min. The conductivity increases gradually until the titration was completed, which was  
759 indicated by a sharp increase in the measured conductivity. The ionic capacity (mmol  $\text{Cl}^-$  /ml  
760 adsorbent) of the adsorbent is equal to the amount of  $\text{AgNO}_3$  (mmol) added per unit volume of  
761 adsorbent.

762

763 **4.2.7. Flow-through chromatography of *E. coli* homogenate and chromatography of SEC-**  
764 **purified HB-VLPs**

765           Similar to Section 3.2.5., the FC of HB-VLPs was performed with a fast protein liquid  
766 chromatography system. Following the protocol provided by the supplier (BioToolomics,  
767 United Kingdom), the column was slurry-packed with adsorbents to a volume of 1.0 ml. First,  
768 the column was equilibrated with 5 ml of Buffer A (25 mM Tris-HCl; pH 8.0). Next, 0.5 ml  
769 of feed [clarified homogenate (5.8 mg of total proteins and 35.5 – 37.0 % of HB-VLPs)] was  
770 loaded to the packed column. Then, 2.5 ml of Buffer A was flowed through the column. Next,  
771 the column was flushed with 0.2 ml of Buffer A to wash off the unbound proteins. Lastly, an  
772 isocratic elution was performed using Buffer B (11 ml; 25 mM Tris-HCl; pH 8.0; 1 M NaCl).

773           A similar protocol was used for the chromatography of SEC-purified HB-VLPs.  
774 However, 0.5 ml of SEC-purified HB-VLPs with protein concentration of 1 mg/ml at 92%  
775 purity was injected (loaded).

776

777 **4.2.8. Quantification of protein**

778           For SEC-purified HB-VLPs, the ratio of flow-through and eluted protein with respect  
779 to total protein loaded was determined from the area under curve of the chromatograms.


780           For FC using *E. coli* feedstock, protein concentration of collected fractions was  
781 determined using the Bradford assay [86]. The purity of HB-VLPs of a collected fraction was  
782 evaluated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as  
783 outlined in section 3.2.6. [87]. The purity of HB-VLPs was determined as the ratio of the  
784 intensity of the HBcAg band to that of all the protein bands, as described by Tey et al. [75].

785

## 786 4.3. Results and Discussion

### 787 4.3.1. Characterization of adsorbents

788 The presence of polymer graft on the modified adsorbents was confirmed qualitatively  
789 by ATR-FTIR analysis. As shown in Figure 9, the characteristic stretching vibration of the  
790 carbonyl group (C=O) at  $1730\text{ cm}^{-1}$  indicates the presence of POEGMA on the following  
791 modified adsorbents: QFF-P200, QFF-P300, QFF-P500, QXL-P200, and QHP-P200.



792

793 **Figure 9.** FTIR spectra of the following adsorbents: (—) QFF-C, (- - -) QFF-P200, (---)  
794 QFF-P300, (.....) QFF-P500, (—) QXL-C, (- - -) QXL-P200, (- - -) QHP-C, (—)  
795 QHP-P200.

796

797 Based on Table 2, the % weight of POEGMA grafted for QFF-P500 adsorbent with  
798 respect to the control adsorbent QFF-C was lower than the % weights of QFF-P200 and QFF-  
799 P300. This indicated a lower amount of POEGMA grafted on QFF-P500 adsorbent. On the  
800 other hand, QXL-P200 adsorbent, which was pre-grafted with charged dextran, exhibited a  
801 higher amount of POEGMA grafted compared to QFF-P200. The grafting of POEGMA  
802 requires hydroxyl group as the initiating site for polymerization. The hydroxyl groups on the

803 dextran grafts of QXL-P200 adsorbent resulted in a higher overall number of accessible  
 804 hydroxyl groups for initiation and consequently a higher amount of POEGMA grafted.

805 As shown in Table 3, the % difference weight of QFF-P200 adsorbent was lower than  
 806 that of QHP-P200 adsorbent. This is because the larger adsorbent possess a lower amount of  
 807 accessible site for initiation and polymer growth, which in turn caused a lower amount of  
 808 polymer grafted.

809 The charged dextran grafts on QXL and the smaller size of QHP leads to more  
 810 accessible binding sites and resulted in a higher ionic capacity (ligand density) measured.  
 811 Meanwhile, the grafting of POEGMA on three types of adsorbents only slightly changed ionic  
 812 capacity as measured using silver nitrate titration method (Table 3).

813

814 **Table 3.** Ionic capacity of adsorbents and the TGA results of modified adsorbents with respect  
 815 to its unmodified controls

| Adsorbent | Adsorbent size <sup>a</sup> (μm) | Ionic capacity <sup>b</sup> (mmol Cl <sup>-</sup> / g adsorbent) | % difference weight loss |
|-----------|----------------------------------|--|--------------------------|
| QFF-C     | 90                               | 0.092  | -                        |
| QFF-P200  | 90                               | 0.091  | 3.33                     |
| QFF-P300  | 90                               | 0.089  | 3.73                     |
| QFF-P500  | 90                               | 0.089  | 1.93                     |
| QXL-C     | 90                               | 0.271  |                          |
| QXL-P200  | 90                               | 0.266  | 12.42                    |
| QHP-C     | 35                               | 0.247  |                          |
| QHP-P200  | 35                               | 0.239  | 10.29                    |

816 <sup>a</sup> According to manufacturer's data

817 <sup>b</sup> From titration of AgNO<sub>3</sub>

818


### 819 4.3.2. Effect of adsorbent size on HB-VLPs adsorption

820 The chromatography of SEC-purified HB-VLPs using adsorbents with different sizes  
 821 was conducted. As both are standard diffusive adsorbents with similar pore size of 50-100 nm  
 822 (with exclusion limit [Mr] [Globular Proteins] of 4x10<sup>6</sup> Da) [94–96], the larger adsorbents are

823 expected to show a low adsorption of HB-VLPs, and are likely to have a better flow-through  
824 recovery of HB-VLP from *E. coli* homogenate in FC.

825           From Figure 10(a), it can be observed that the smaller QFF-C showed a higher flow-  
826 through of SEC-purified HB-VLPs as compared to the larger QHP-C. Similarly, the FC of *E.*  
827 *coli* homogenate using QFF-C demonstrated a higher flow-through recovery [approximately 2  
828 fold; as shown Figure 10(b)]. The larger adsorbent size of QFF-C resulted in a less accessible  
829 binding sites which consequently reduced undesired adsorption of HB-VLPs and improved its  
830 flow-through recovery.

831



832  
 833 **Figure 10.** (a) Chromatograms of SEC-purified HB-VLP feedstock using adsorbents with  
 834 different size: QHP-C (35  $\mu\text{m}$ ) and QFF-C (90  $\mu\text{m}$ ), with QHP-P200 and QFF-P200  
 835 representing the respective adsorbent grafted with POEGMA<sub>200</sub>. Absorbance (mAU) for (—)  
 836 QHP-C, (-.-) QHP-P200, (—) QFF-C, and (-.-) QFF-P200; and (---) conductivity  
 837 (mS/cm) against volume of buffer (ml) flowed in the column. (b) Flow-through recovery and  
 838 PF of HB-VLP from *E. coli* homogenate


839

840 As the  $D_H$  of HB-VLPs [30 nm, as shown in Figure 11(b)] is smaller than the  
841 adsorbent's pore size (50-100 nm), the anion exchange adsorbents were grafted with POEGMA  
842 to further reduce unwanted adsorption of HB-VLPs. As shown in Figure 10(a), the QFF-P200  
843 adsorbent (with POEGMA<sub>200</sub> grafts) showed a higher flow-through of SEC-purified HB-VLPs,  
844 in comparison to its ungrafted control (QFF-C). As such, QFF-P200 successfully reduced the  
845 HB-VLP in FC mode, thereby giving the higher recovery and PF of HB-VLPs (as shown in  
846 Figure 10(b)). However, a significant drop of PF was shown for smaller QHP-P200, likely  
847 caused by the high amount of POEGMA grafted (as shown in Table 3), which in turn result in  
848 excessive diffusional resistance on HCPs. This leads to an undesired reduction in HCPs  
849 adsorption, lowering the flow-through PF. Other example of excessive resistance to protein  
850 diffusion in agarose-coated FC adsorbents was also reported [63].

851 The effect of POEGMA on adsorption SEC-purified HB-VLPs can be observed in  
852 Figure 10(a) - lower amount was eluted at a higher conductivity, indicating a reduction in strong  
853 multipoint adsorption of SEC-purified HB-VLP on the adsorbent, that have been shown to  
854 cause disintegration of VLPs as reported by Huang et al. [32]. Dynamic light scattering results  
855 based on particle size's volume distribution in Figure 11(b) showed that QHP adsorbents with  
856 high capacity (high ligand density) caused most of the eluted HB-VLPs to disintegrate ( the  
857 size of the eluted proteins are less than 10 nm). In comparison, the proteins eluted from QFF-  
858 C and QFF-P200 contain significantly more intact HB-VLP (protein in the 10-30 nm range).  
859 Additionally, eluted fraction of polymer grafted QFF-P200 was found to contain more intact  
860 HB-VLP (35%) range compared to its ungrafted control (19%).

861 As most of the smaller HCPs was adsorbed in FC mode, Figure 11(a) showed that  
862 proteins in flow-through fractions (average: 37 nm) were generally larger than the proteins in

863 the feedstock (46 % average: 21 nm; 54% average: 37 nm) in Figure 11(c). Besides, protein  
864 size profile of flow-through fractions of QFF-C and QFF-P200 generally closely resembles the  
865 size distribution of SEC-purified HB-VLPs, indicating minimal disassembly of HB-VLPs in  
866 the flow-through has occurred. The protein size analysis also showed that the use of QFF-P200  
867 resulted in a flow-through fraction with slightly larger proteins, confirming the role of  
868 POEGMA in improving the size-selective effect of QFF.



869

870 **Figure 11.** Size distribution in terms of volume based distribution of proteins collected in the  
 871 a) flow-through fractions, and b) eluted fractions of adsorbents (—) QHP-C, (---) QHP-  
 872 P200, (—) QFF-C, and (---) QFF-P200, and c) (—) *E. coli* feedstock and (·····) SEC-  
 873 purified HB-VLPs.

874


875 In general, the QHP-C adsorbent provides a better PF but a low recovery of HB-VLP  
876 [Figure 10(b)], indicating that a smaller adsorbent will be ill-suited for an initial capture of  
877 clarified feed. Additionally, POEGMA grafted QFF-P200 was shown to effectively reduced  
878 disintegration of eluted protein and strongly adsorbed SEC-purified HB-VLPs.

879

#### 880 **4.3.3. Comparison between charged dextran grafts and POEGMA grafts for FC**

881 Charged dextran grafts grafted on ion exchange adsorbents was known to significantly  
882 improve the adsorption capacity of small proteins, while being restrictive towards the large  
883 biomacromolecules as it possess significantly smaller apparent pore size [97]. Consequently,  
884 the dextran grafts should aid in the exclusion of large HB-VLPs. However, Figure 12 showed  
885 that QXL-C adsorbent showed a lower flow-through recovery compared to QFF-P200, with  
886 only modest increase in PF. It is likely that the additional binding sites on the charged dextran  
887 has increased the adsorption of both HB-VLPs and HCPs.

888



889

890 **Figure 12.** Flow-through recovery and PF of HB-VLP from *E. coli* homogenate using standard  
 891 adsorbents QFF-C, adsorbents grafted with POEGMA<sub>200</sub> (QFF-P200), Sepharose XL  
 892 adsorbents (QXL-C) and POEGMA grafted QXL-P200

893

894 As illustrated in Figure 13 , the QXL-P200 adsorbent represents the combined effect  
 895 of charged dextran and POEGMA grafts on the performance of the adsorbents. As shown in  
 896 Figure 12, POEGMA grafted on QFF-P200 resulted in better flow-through recovery and PF  
 897 compared to its control QFF-C. In contrast, the POEGMA on QXL-P200 resulted in a lower  
 898 (5.3 %) flow-through recovery with its control QXL-C. This could be due to the protein (HB-  
 899 VLPs) entrapment by the grafted polymer has been reported by Lee et al. [63]. Since much  
 900 more POEGMA<sub>200</sub> was grafted on QXL-P200 (Table 3), the restricted pores and the  
 901 combined dextran and POEGMA grafts could have trapped HB-VLPs and contributed to a  
 902 lower flow-through recovery and PF.


903 Despite the smaller apparent pore size of QXL adsorbents, the additional binding sites  
 904 on dextran grafts affected the flow-through recovery and PF. Based on the current findings, the  
 905 adsorbent grafted with POEGMA outperformed the adsorbent grafted with dextran, due to  
 906 POEGMA's non-charged and inert properties.

907

#### 908 **4.3.4. Effect of the branch chain length of grafted POEGMA**

909 Polymer architecture also plays a pivotal role in reducing the diffusion of larger VLPs  
910 to the surface of the POEGMA grafted adsorbents. The length of branch-chain of the grafted  
911 POEGMA was varied by using different OEGMA monomers for polymerization. In this study,  
912 an increase in the repeating unit of ethylene oxide (branch-chain) was expected to increase the  
913 steric hindrances exerted on large protein, such as HB-VLPs.

914 The improvement of exclusion provided by increasing branch chain length was partially  
915 offset by significant reduction in amount of polymer grafted (Table 3). Hence, from Figure  
916 14(a), flow-through recovery and PF of QFF-P300 are only slightly better than QFF-P200.  
917 POEGMA<sub>500</sub> showed a better performance in PF but lower flow through recovery compared to  
918 POEGMA<sub>300</sub>. The lower flow through recover obtained in POEGMA<sub>500</sub> is most probably due  
919 to its lower amount of polymer grafted. The longer and more hydrophilic branch-chain forms  
920 a thicker hydration layer [74], thus POEGMA<sub>500</sub> is more effective at reducing the interaction  
921 between HB-VLPs and Q ligands as illustrated in Figure 13(b). Optimisation of polymerisation  
922 condition could increase the amount of POEGMA<sub>500</sub> grafted.




923

924 **Figure 13.** Illustration of size-selective exclusion of the HB-VLPs and the larger HCPs from  
 925 the external surface of adsorbents. The smaller HCPs are able to approach the external surface  
 926 and pores in the adsorbent. (a) Adsorption of HB-VLPs on the additional binding sites of grafts  
 927 on the unmodified Sepharose XL adsorbent (QXL-C); the dense POEGMA<sub>200</sub> grafts on QXL-  
 928 P200 adsorbent reduced the diffusion of HCPs to external surface of the adsorbent, and (b)  
 929 Sepharose Q grafted with POEGMA of increasing side chain length increased the exclusion of  
 930 larger HCPs and HB-VLPs

931

932 Besides, the adsorbents modified with POEGMA (i.e., QFF-P200, QFF-P300 and QFF-  
 933 P500 adsorbents) showed a modest improvement of PF and flow-through recovery compared  
 934 to ungrafted control- approximately 5%. As discussed in Section 3.3.3., the limited  
 935 improvement was likely due to a small but significant fraction of HCPs that were larger in size,  
 936 causing more HCPs in the flow-through fraction along with the target HB-VLPs that  
 937 consequently reduces the purity of the flow-through fractions.



938

939 **Figure 14.** (a) Flow-through recovery and PF of FC of HB-VLPs from *E. coli* homogenate and  
 940 (b) SDS-PAGE results of the feed and flow-through fractions collected. Lanes 1, 2, 3 and 4  
 941 represents the fractions purified with QFF-C, QFF-P200, QFF-P300 and QFF-P500  
 942 respectively, while (a) represents the first half of flow-through fraction collected and (b)  
 943 represents the second half of flow-through fraction collected.

944 Trillisky *et al.* [89] postulated that the biomolecules with approximately the same size  
945 as the pores of the adsorbent can lead to the convective entrapment of biomolecules in the  
946 pores. Since the presence of POEGMA polymer on the adsorbent was likely to constrict the  
947 pores, an elevated level of protein loss due to the convective entrapment could be expected.  
948 Such entrapment within agarose coated adsorbent has also been reported by our previous study  
949 [63]. On the other hand, protein trapped within polymer seemed to improve the flow-through  
950 recovery of HB-VLPs. The multi-cycle of chromatographic runs of modified adsorbents  
951 seemed to reduce the protein loss. For instance, using the adsorbent QFF-P300, the total protein  
952 loss in the first, second and third cycle were 16.5%, 15.9%, 13.7% respectively. Therefore, an  
953 extensive cyclical test is required to further explore the reusability of the adsorbents.

954

#### 955 **4.4. Conclusion**

956 From study of Phase 2, the POEGMA-grafted adsorbents were successfully  
957 synthesized via free radical graft polymerization approach. The larger-size Q Sepharose FF  
958 showed a lower adsorption of HB-VLPs, which is a key factor in achieving a better flow-  
959 through recovery. The size-selective properties of POEGMA-grafted adsorbents were  
960 qualitatively verified as the protein size of the recovered fraction was found to be larger  
961 compared to its ungrafted control. Additionally, POEGMA grafted QFF-P200 effectively  
962 reduces disintegration of eluted protein and strongly adsorbed SEC-purified HB-VLPs. When  
963 compared to the dextran-grafted QXL-C adsorbent, the inert POEGMA produced a better flow-  
964 through recovery of HB-VLPs. Despite the small pore size of QXL-C adsorbents, the additional  
965 binding sites on dextran grafts affected the performance of FC. Study of branch-chain length  
966 of POEGMA showed that the long-chain POEGMA<sub>500</sub> produced comparable performance even  
967 at a low polymer grafting density. In conclusion, although the modified adsorbent QFF-P300

968 was able to provide a sufficient exclusion effect for HB-VLPs with flow-through recovery of  
969 92% and PF of 1.53- a 5% improvement of recovery compared to the POEGMA<sub>200</sub> designed by  
970 the previous study. However, a case-by-case tailored adsorbent is required for the exclusion of  
971 other target biomolecules of different surface charge density and size.

972

973

## 974 **Chapter 5: General Discussion, Conclusion and Recommendation** 975 **for the Future Work**

### 976 **5.1. General discussion**

977 Phase 1 aimed to identify suitable feedstock condition (protein load, target protein  
978 size) for FC. The results obtained from the comparative study between HB-tridimer and HB-  
979 VLP, the capacity of impurities removal with HB-VLPs is significantly reduced (70%),  
980 hence, larger amount of adsorbent is needed in the operation with HB-VLP feedstock. The  
981 optimum range of protein load of feedstock HB-VLPs for Sepharose Q FF adsorbent was  
982 found to be at 30% HCPs breakthrough. The repulsion effect of adsorbed HB-VLPs resulted  
983 in a decrease in optimum protein load to 15% HCPs breakthrough or 5.5 mg total protein/ml  
984 adsorbent for POEGMA grafted adsorbent. Optimal feedstock condition obtained for polymer  
985 modified adsorbent was similar to previous study [14,63]. Compared to feedstock with low  
986 purity VLPs such as MrN-VLPs, highly expressed HB-VLPs was more suitable to be purified  
987 using FC.

988 Phase 2 aimed to improve the design of polymer grafted adsorbent for FC. Larger  
989 adsorbent was found to provide better flow-through recovery with an offset to purity, while  
990 the inert (non-charged) properties of POEGMA was found to be suited for FC applications.  
991 OEGMA monomer with longer branch chain length results in POEGMA that is more  
992 hydrophilic, producing comparable flow-through recovery and purity despite lower grafted  
993 amount. Adsorbent grafted with moderate branch chain length (QFF-P300) was found to  
994 provide better (approximately 5%) FC performance compared to short branch chain length  
995 (QFF-P200) of previous study by our research group [63].

996

997 **5.2. Conclusion**

998 For the initial isolation step of HB-VLPs from its clarified *E. coli* homogenate, the  
999 current study successfully identified suitable condition of feedstock in the FC mode using  
1000 POEGMA grafted cationized adsorbent. The optimal condition is at 5.5 mg total protein/ml  
1001 of adsorbent. While the 2<sup>nd</sup> phase established standard size diffusive adsorbents grafted with  
1002 moderate branch chain (QFF-P300) as the optimal adsorbent design suitable for the intended  
1003 application. Compared to the previous study, slight improvement in flow-through recovery of  
1004 HB-VLPs was achieved with longer branch chain length POEGMA<sub>300</sub> – with a flow-through  
1005 recovery of 92% and PF of 1.53. Further work are recommended to improve the performance  
1006 of the adsorbents as well as establish a platform for the VLP purification.

1007

1008 **5.3. Recommendations for future work**

1009 The feedstock condition can be improved further for FC operation. The amount of  
1010 residual DNA can be measured and treated with nucleases prior to chromatography. Since the  
1011 size of DNAs are similar to HB-VLPs [59], and are likely to be excluded along with the  
1012 target protein. Addition of nucleases could reduce the size of DNA and improve its  
1013 adsorption and removal. Besides, large HCPs was observed in the flowthrough fractions.  
1014 Adding an ultra/diafiltration step before the negative chromatography could help to eliminate  
1015 the impurities before the negative chromatography. However, the cost of the additional step  
1016 should be taken into account.

1017           The design of the adsorbent can also be improved further. For instance, the grafting  
1018 density can be improved by adopting other grafting reaction or technique. Atom transfer  
1019 radical polymerization (ATRP) from immobilized initiators otherwise known as ‘Grafting  
1020 from’ techniques allow precise control over grafting density [98]. This would in turn allow  
1021 better control of the size selective properties i.e. a more defined molecular weight cut-off that  
1022 would in turn improve applicability for different feedstock. Extensive cyclical test should be  
1023 conducted to establish the reusability of the POEGMA grafted adsorbents as protein  
1024 entrapment was found to be an issue.

1025

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037 **References**

- 1038 [1] Pumpens, P., Grens, E., HBV core particles as a carrier for B cell / T cell epitopes.  
1039 *Intervirology* 2001, 1067, 98–114.
- 1040 [2] Wolf, M. W., Reichl, U., Downstream processing of cell culture-derived virus  
1041 particles. *Expert Rev. Vaccines* 2011, 10, 1451–1475.
- 1042 [3] Rolland, D., Gauthier, M., Dugua, J. M., Fournier, C., Delpech, L., Watelet, B.,  
1043 Letourneur, O., Arnaud, M., Jolivet, M., Purification of recombinant HBc antigen  
1044 expressed in *Escherichia coli* and *Pichia pastoris*: Comparison of size-exclusion  
1045 chromatography and ultracentrifugation. *J. Chromatogr. B Biomed. Sci. Appl.* 2001,  
1046 753, 51–65.
- 1047 [4] Ng, M. Y. T., Tan, W. S., Abdullah, N., Ling, T. C., Tey, B. T., Direct purification of  
1048 recombinant hepatitis B core antigen from two different pre-conditioned unclarified  
1049 *Escherichia coli* feedstocks via expanded bed adsorption chromatography. *J.*  
1050 *Chromatogr. A* 2007, 1172, 47–56.
- 1051 [5] Yu, M., Li, Y., Zhang, S., Li, X., Yang, Y., Chen, Y., Ma, G., Su, Z., Improving  
1052 stability of virus-like particles by ion-exchange chromatographic supports with large  
1053 pore size: Advantages of gigaporous media beyond enhanced binding capacity. *J.*  
1054 *Chromatogr. A* 2014, 1331, 69–79.
- 1055 [6] DePhillips, P., Lenhoff, A. M., Pore size distributions of cation-exchange adsorbents  
1056 determined by inverse size-exclusion chromatography. *J. Chromatogr. A* 2000, 883,  
1057 39–54.
- 1058 [7] Gagnon, P., The emerging generation of chromatography tools for virus purification.  
1059 *Bioprocess Int.* 2008, 6, Suppl. 6 24-30.

- 1060 [8] Wu, Y., Abraham, D., Carta, G., Particle size effects on protein and virus-like particle  
1061 adsorption on perfusion chromatography media. *J. Chromatogr. A* 2015, 1375, 92–  
1062 100.
- 1063 [9] Wu, Y., Simons, J., Hooson, S., Abraham, D., Carta, G., Protein and virus-like particle  
1064 adsorption on perfusion chromatography media. *J. Chromatogr. A* 2013, 1297, 96–  
1065 105.
- 1066 [10] Weigel, T., Solomaier, T., Peuker, A., Pathapati, T., Wolff, M. W., Reichl, U., A flow-  
1067 through chromatography process for influenza A and B virus purification. *J. Virol.*  
1068 *Methods* 2014, 207, 45–53.
- 1069 [11] Wang, C., Soice, N. P., Ramaswamy, S., Gagnon, B. A., Umana, J., Cotoni, K. A.,  
1070 Bian, N., Cheng, K.-S. C., Cored anion-exchange chromatography media for antibody  
1071 flow-through purification. *J. Chromatogr. A* 2007, 1155, 74–84.
- 1072 [12] Blom, H., Åkerblom, A., Kon, T., Shaker, S., Pol, L. Van Der, Lundgren, M., Efficient  
1073 chromatographic reduction of ovalbumin for egg-based influenza virus purification.  
1074 *Vaccine* 2014, 32, 3721–3724.
- 1075 [13] Yoon, K. Y., Tan, W. S., Lee, K. W., Ho, K. L., Native agarose gel electrophoresis and  
1076 electroelution : A fast and cost-effective method to separate the small and large  
1077 hepatitis B capsids. *Electrophoresis* 2013, 34, 244–253.
- 1078 [14] Lee, M. F. X., Chan, E. S., Tan, W. S., Tam, K. C., Tey, B. T., Negative  
1079 chromatography purification of hepatitis B virus-like particles using  
1080 poly(oligo(ethylene glycol) methacrylate) grafted cationic adsorbent. *J. Chromatogr. A*  
1081 2015, 1415, 161–165.
- 1082 [15] Zeltins, A., Construction and characterization of virus-like particles: A review. *Mol.*

- 1083 *Biotechnol.* 2013, 53, 92–107.
- 1084 [16] Shirbaghaee, Z., Bolhassani, A., Different applications of virus-like particles in  
1085 biology and medicine: Vaccination and delivery systems. *Biopolymers* 2016, 105,  
1086 113–132.
- 1087 [17] Roldao, A., Mellado, M. C. M., Castilho, L. R., Carrondo, M. J., Alves, P. M., Virus-  
1088 like particles in vaccine development. *Expert Rev. Vaccines* 2010, 9, 1149–1176.
- 1089 [18] Lua, L. H. L., Connors, N. K., Sainsbury, F., Chuan, Y. P., Wibowo, N., Middelberg,  
1090 A. P. J., Bioengineering virus-like particles as vaccines. *Biotechnol. Bioeng.* 2014,  
1091 111, 425–440.
- 1092 [19] Huang, Y., Bi, J., Zhou, W., Li, Y., Wang, Y., Ma, G., Su, Z., Improving recovery of  
1093 recombinant hepatitis B virus surface antigen by ion-exchange chromatographic  
1094 supports with low ligand density. *Process Biochem.* 2006, 41, 2320–2326.
- 1095 [20] Vanlandschoot, P., Cao, T., Leroux-roels, G., The nucleocapsid of the hepatitis B  
1096 virus : a remarkable immunogenic structure. *Antiviral Res.* 2003, 60, 67–74.
- 1097 [21] Schodel, F., Peterson, D., Milich, D., Hepatitis B virus core and e antigen: immune  
1098 recognition and use as a vaccine carrier moiety. *Intervirology* 1996, 39, 104–110.
- 1099 [22] Elvidge, S., Blockbuster expectations for hepatitis B therapeutic vaccine. *Nat.*  
1100 *Biotechnol.* 2015, 789.
- 1101 [23] Morenweiser, R., Downstream processing of viral vectors and vaccines. *Gene Ther.*  
1102 2005, 12 Suppl 1, S103-10.
- 1103 [24] Palenzuela, D. O., Núñez, L., Roca, J., Acevedo, B., Díaz, T., Benítez, J., Gavilondo,  
1104 J. V., Purification of the recombinant hepatitis B core antigen, and its potential use for  
1105 the diagnosis of Hepatitis B virus infection. *Biotechnol. Apl.* 2002, 19, 138–142.

- 1106 [25] Ng, M. Y. T., Tan, W. S., Abdullah, N., Ling, T. C., Tey, B. T., Heat treatment of  
1107 unclarified *Escherichia coli* homogenate improved the recovery efficiency of  
1108 recombinant hepatitis B core antigen. *J. Virol. Methods* 2006, 137, 134–139.
- 1109 [26] Wolff, M. W., Reichl, U., Downstream processing: From egg to cell culture-derived  
1110 influenza virus particles. *Chem. Eng. Technol.* 2008, 31, 846–857.
- 1111 [27] Carta, G., Jungbauer, A., Protein Chromatography. 2010, pp. 85–124.
- 1112 [28] Wu, Y., Simons, J., Hooson, S., Abraham, D., Carta, G., Protein and virus-like particle  
1113 adsorption on perfusion chromatography media. *J. Chromatogr. A* 2013, 1297, 96–  
1114 105.
- 1115 [29] Sviben, D., Forcic, D., Ivancic-Jelecki, J., Halassy, B., Brgles, M., Recovery of  
1116 infective virus particles in ion-exchange and hydrophobic interaction monolith  
1117 chromatography is influenced by particle charge and total-to-infective particle ratio. *J.*  
1118 *Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2017, 1054, 10–19.
- 1119 [30] Yang, Y., Mengran Yu, Zhang, S., Ma, G., Su, Z., Adsorption of virus-like particles on  
1120 ion exchange surface: Conformational changes at different pH detected by dual  
1121 polarization interferometry. *J. Chromatogr. A* 2015, 1408, 161–168.
- 1122 [31] Iyer, G., Ramaswamy, S., Asher, D., Mehta, U., Leahy, A., Chung, F., Cheng, K.-S.,  
1123 Reduced surface area chromatography for flow-through purification of viruses and  
1124 virus like particles. *J. Chromatogr. A* 2011, 1218, 3973–81.
- 1125 [32] Huang, Y., Bi, J., Zhao, L., Ma, G., Su, Z., Regulation of protein multipoint adsorption  
1126 on ion-exchange adsorbent and its application to the purification of macromolecules.  
1127 *Protein Expr. Purif.* 2010, 74, 257–63.
- 1128 [33] Lu, X., Zhao, D., Ma, G., Su, Z., Polyethylene glycol increases purification and

- 1129 recovery , alters retention behavior in flow-through chromatography of hemoglobin. *J.*  
1130 *Chromatogr. A* 2004, 1059, 233–237.
- 1131 [34] Wang, Y., Zhang, P., Liu, S., Zhang, Y., Zhao, T., Huang, W., He, C., Yu, Y., Wang,  
1132 L., Wan, M., Purification of IgG from sera of rabbit and guinea pig by flow-through  
1133 mode ion-exchange chromatography using DEAE sepharose fast flow column.  
1134 *Chromatographia* 2011, 74, 209–214.
- 1135 [35] Burbelo, P., Kisailus, A., Peck, J. W., Negative purification method for the selection of  
1136 specific antibodies from polyclonal antisera. *Biotechniques* 2002, 33, 1050–1054.
- 1137 [36] Bjerke, T., Nielsen, S., Helgestad, J., Nielsen, B. W., Purification of human blood  
1138 basophils by negative selection using immunomagnetic beads. *J. Immunol. Methods*  
1139 1993, 157, 49–56.
- 1140 [37] Neale, A. D., Scopes, R. K., Kelly, J. M., Wettenhall, E. H., The two alcohol  
1141 dehydrogenases of *Zymomonas mobilis* and physiological roles. *Eur. J. Biochem.*  
1142 1986, 154, 119–124.
- 1143 [38] Hey, Y., Dean, P. D., Tandem dye-ligand chromatography and biospecific elution  
1144 applied to the purification of glucose-6-phosphate dehydrogenase from *Leuconostoc*  
1145 *mesenteroides*. *Biochem. J.* 1983, 209, 363–371.
- 1146 [39] Scopes, R. K., Griffiths-Smith, K., Use of differential dye-ligand chromatography with  
1147 affinity elution for enzyme purification: 6-Phosphogluconate dehydratase from  
1148 *Zymomonas mobilis*. *Anal. Biochem.* 1984, 136, 530–534.
- 1149 [40] Pitiot, O., Nedonchelle, E., Vijayalakshmi, M. A., Protein adsorption on histidyl-  
1150 aminohexyl-Sepharose 4B II . Application to the negative one-step affinity purification  
1151 of human b 2-microglobulin and Immunoglobulin G. 2001, 758, 173–182.

- 1152 [41] Cristiane, M., Souza, M. De, Tadeu, I., Bresolin, L., Maria, S., Bueno, A., Purification  
1153 of human IgG by negative chromatography on  $\omega$ -aminohexyl-agarose. *J. Chromatogr.*  
1154 *B* 2010, 878, 557–566.
- 1155 [42] Bresolin, I. T. L., de Souza, M. C. M., Bueno, S. M. A., A new process of IgG  
1156 purification by negative chromatography: Adsorption aspects of human serum proteins  
1157 onto  $\alpha$ -aminodecyl-agarose. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2010,  
1158 878, 2087–2093.
- 1159 [43] Bresolin, I. ., Fioritti, R., Bueno, S., IgG purification by negative chromatography in  
1160 amine-based ligands : A comparison of l -lysine and poly- l -lysine. *Process Biochem.*  
1161 2011, 46, 2277–2285.
- 1162 [44] Brooks, S. P., Storey, K. B., Purification and characterization of a protein phosphatase  
1163 that dephosphorylates pyruvate kinase in an anoxia tolerant animal. *Biochem. Mol.*  
1164 *Biol. Int.* 1996, 38, 1223–34.
- 1165 [45] Lu, X., Zhao, D., Su, Z., Purification of hemoglobin by ion exchange chromatography  
1166 in flow-through mode with PEG as an escort purification of hemoglobin by ion  
1167 exchange. *Artif. Cells, Blood Substitutes, Biotechnol.* 2009, 32, 209–227.
- 1168 [46] Wongchuphan, R., Tey, T., Siang, W., Kumar, S., Saleena, F., Chuan, T., Purification  
1169 of rabbit polyclonal immunoglobulin G using anion exchangers. *Process Biochem.*  
1170 2011, 46, 101–107.
- 1171 [47] Champion, K. M., Nishihara, J. C., Joly, J. C., Arnott, D., Similarity of the *Escherichia*  
1172 *coli* proteome upon completion of different biopharmaceutical fermentation processes.  
1173 *Proteomics* 2001, 1, 1133–1148.
- 1174 [48] Zheng, J., Schodel, F., Peterson, D. L., The structure of hepadnaviral core antigens.

- 1175 Identification of free thiols and determination of the disulfide bonding pattern. *J. Biol.*  
1176 *Chem.* 1992, 267, 9422–9429.
- 1177 [49] Yoshida, H., Morita, I., Tamai, G., Masujima, T., Tsuru, T., Takai, N., Imai, H., Some  
1178 characteristics of a protein-coated ODS column and its use for the determination of  
1179 drugs by the direct injection analysis of plasma samples. *Chromatographia* 1984, 19,  
1180 466–472.
- 1181 [50] Souverain, S., Rudaz, S., Veuthey, J. L., Restricted access materials and large particle  
1182 supports for on-line sample preparation: An attractive approach for biological fluids  
1183 analysis. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2004, 801, 141–156.
- 1184 [51] Cassiano, N. M., Lima, V. V., Oliveira, R. V., De Pietro, A. C., Cass, Q. B.,  
1185 Development of restricted-access media supports and their application to the direct  
1186 analysis of biological fluid samples via high-performance liquid chromatography.  
1187 *Anal. Bioanal. Chem.* 2006, 384, 1462–1469.
- 1188 [52] Yang, S. H., Fan, H., Classon, R. J., Schug, K. A., Restricted access media as a  
1189 streamlined approach toward on-line sample preparation: Recent advancements and  
1190 applications. *J. Sep. Sci.* 2013, 36, 2922–2938.
- 1191 [53] Kanda, T., Kutsuna, H., Ohtsu, Y., Yamaguchi, M., Synthesis of polymer-coated  
1192 mixed-functional packing materials for direct analysis of drug-containing serum and  
1193 plasma by high-performance liquid chromatography. *J. Chromatogr. A* 1994, 672, 51–  
1194 57.
- 1195 [54] Katagi, M., Nishikawa, M., Tatsuno, M., Miki, A., Tsuchihashi, H., Column-switching  
1196 high-performance liquid chromatography-electrospray ionization mass spectrometry  
1197 for identification of heroin metabolites in human urine. *J. Chromatogr. B Biomed. Sci.*  
1198 *Appl.* 2001, 751, 177–185.

- 1199 [55] Tian, R., Zhang, H., Ye, M., Jiang, X., Hu, L., Li, X., Bao, X., Zou, H., Selective  
1200 extraction of peptides from human plasma by highly ordered mesoporous silica  
1201 particles for peptidome analysis. *Angew Chem Int Ed Engl* 2007, 46, 962–965.
- 1202 [56] Hu, L., Zhou, H., Li, Y., Sun, S., Guo, L., Ye, M., Tian, X., Gu, J., Yang, S., Zou, H.,  
1203 Profiling of endogenous serum phosphorylated peptides by titanium (IV) immobilized  
1204 mesoporous silica particles enrichment and MALDI-TOFMS detection. *Anal. Chem.*  
1205 2009, 81, 94–104.
- 1206 [57] Jahanshahi, M., Zhang, Z., Lyddiatt, A., Subtractive chromatography for purification  
1207 and recovery of nano-bioproducts. *IEEE Proc. nanobiotechnology* 2005, 152, 207–  
1208 211.
- 1209 [58] Jahanshahi, M., Aghajani, H., Ling, T., Assembly and purification of nanostructure  
1210 bioproducts: Protein nanoparticle characterization and non-stick exterior coating  
1211 adsorbents. *Int. J. Nanosci. Nanotechnol* 2005, 1, 9–20.
- 1212 [59] Gustavsson, P., Lemmens, R., Nyhammar, T., Busson, P., Larsson, P., Purification of  
1213 plasmid DNA with a new type of anion-exchange beads having a non-charged surface.  
1214 *J. Chromatogr. A* 2004, 1038, 131–140.
- 1215 [60] GE Healthcare, L. S., GE Healthcare Life Sciences “Q and SP Sepharose™ Big  
1216 Beads.”
- 1217 [61] GE Healthcare, L. S., GE Healthcare Life Sciences “Capto™ Core 700.”
- 1218 [62] Nestola, P., Peixoto, C., Villain, L., Alves, P. M., Carrondo, M. J. T., Mota, P. B.,  
1219 Rational development of flow-through purification strategies for viruses and virus-like  
1220 particles. *J. Chromatogr. A* 2015, 1426, 1–39.
- 1221 [63] Lee, M. F. X., Chan, E. S., Tan, W. S., Tam, K. C., Tey, B. T., Negative

- 1222 chromatography of hepatitis B virus-like particle: Comparative study of different  
1223 adsorbent designs. *J. Chromatogr. A* 2016, 1445, 1–9.
- 1224 [64] Lee, M. F. X., Chan, E. S., Tan, W. S., Tam, K. C., Tey, B. T., Negative  
1225 chromatography purification of hepatitis B virus-like particles using  
1226 poly(oligo(ethylene glycol) methacrylate) grafted cationic adsorbent. *J. Chromatogr. A*  
1227 2015, 1415, 161–165.
- 1228 [65] Jeon, S. ., Lee, J. ., Andrade, J. ., De Gennes, P. ., Protein—surface interactions in the  
1229 presence of polyethylene oxide. *J. Colloid Interface Sci.* 1991, 142, 149–158.
- 1230 [66] Lowe, S., O’Brien-Simpson, N. M., Connal, L. A., Antibiofouling polymer interfaces:  
1231 poly(ethylene glycol) and other promising candidates. *Polym. Chem.* 2015, 6, 198–  
1232 212.
- 1233 [67] Heuberger, M., Drobek, T., Spencer, N. D., Interaction forces and morphology of a  
1234 protein-resistant poly(ethylene glycol) layer. *Biophys. J.* 2005, 88, 495–504.
- 1235 [68] Chan, Y. H. M., Schweiss, R., Werner, C., Grunze, M., Electrokinetic characterization  
1236 of oligo- and poly(ethylene glycol)-terminated self-assembled monolayers on gold and  
1237 glass surfaces. *Langmuir* 2003, 19, 7380–7385.
- 1238 [69] Szleifer, I., Protein adsorption on tethered polymer layers: effect of polymer chain  
1239 architecture and composition. *Phys. A Stat. Mech. its Appl.* 1997, 244, 370–388.
- 1240 [70] Hucknall, A., Rangarajan, S., Chilkoti, A., In Pursuit of Zero: Polymer Brushes that  
1241 Resist the Adsorption of Proteins. *Adv. Mater.* 2009, 21, 2441–2446.
- 1242 [71] Tsukagoshi, T., Kondo, Y., Yoshino, N., Protein adsorption on polymer-modified  
1243 silica particle surface. *Colloids Surfaces B Biointerfaces* 2007, 54, 101–107.
- 1244 [72] Yoshikawa, C., Goto, A., Ishizuka, N., Nakanishi, K. K., Kishida, A., Tsujii, Y.,

- 1245 Fukuda, T., Radical Polymerization: Kinetics and Mechanism. WILEY-VCH Verlag  
1246 2007, pp. 189–198.
- 1247 [73] Brooks, D. E., Haynes, C. A., Hritcu, D., Steels, B. M., Müller, W., Size exclusion  
1248 chromatography does not require pores. *Proc. Natl. Acad. Sci. U. S. A.* 2000, 97, 7064–  
1249 7.
- 1250 [74] Gunkel, G., Weinhart, M., Becherer, T., Haag, R., Huck, W. T. S., Effect of polymer  
1251 brush architecture on antibiofouling properties. *Biomacromolecules* 2011, 12, 4169–  
1252 4172.
- 1253 [75] Tey, B. T., Yong, K. H., Ong, H. P., Ling, T. C., Ong, S. T., Tan, Y. P., Ariff, A., Tan,  
1254 W. S., Optimal conditions for hepatitis B core antigen production in shaken flask  
1255 fermentation. *Biotechnol. Bioprocess Eng.* 2004, 9, 374–378.
- 1256 [76] Watelet, B., Quibriac, M., Rolland, D., Gervasi, G., Gauthier, M., Jolivet, M.,  
1257 Letourneur, O., Erratum to “ Characterization and diagnostic potential of hepatitis B  
1258 virus nucleocapsid expressed in *E. coli* and *P. pastoris*”. *J. Virol. Methods* 2002, 102,  
1259 7887.
- 1260 [77] Yap, W. B., Tey, B. T., Alitheen, N. B. M., Tan, W. S., Purification of His-tagged  
1261 hepatitis B core antigen from unclarified bacterial homogenate using immobilized  
1262 metal affinity-expanded bed adsorption chromatography. *J. Chromatogr. A* 2010,  
1263 1217, 3473–3480.
- 1264 [78] Ng, M. Y. T., Siang, W., Tey, T., Purification of recombinant hepatitis B core antigen  
1265 from unclarified *Escherichia coli* feedstock using phage-immobilized expanded bed  
1266 adsorption chromatography. *J. Chromatogr. B* 2012, 903, 60–67.
- 1267 [79] Ho, C. W., Tan, W. S., Kamaruddin, S., Ling, T. C., Tey, B. T., The direct recovery of

- 1268 recombinant hepatitis B core antigen from disruptate derived from continuous-flow  
1269 bead milling. *Biotechnol. Appl. Biochem.* 2008, 50, 49–59.
- 1270 [80] Vennapusa, R., Hunegnaw, S. M., Cabrera, R. B., Fernández-Lahore, M., Assessing  
1271 adsorbent-biomass interactions during expanded bed adsorption onto ion exchangers  
1272 utilizing surface energetics. *J. Chromatogr. A* 2008, 1181, 9–20.
- 1273 [81] Lee, K. W., Tey, B. T., Ho, K. L., Tejo, B. A., Tan, W. S., Nanoglue: An alternative  
1274 way to display cell-internalizing peptide at the spikes of Hepatitis B virus core  
1275 nanoparticles for cell-targeting delivery. *Mol. Pharm.* 2012, 9, 2415–2423.
- 1276 [82] Yoon, K. Y., Expression, Purification and Structural Characterisation of Hepatitis B  
1277 Virus Core Antigen with an N-Terminal Extension, Universiti Putra Malaysia, 2013.
- 1278 [83] Zhu, M., Carta, G., Adsorption of polyethylene-glycolated bovine serum albumin on  
1279 macroporous and polymer-grafted anion exchangers. *J. Chromatogr. A* 2014, 1326,  
1280 29–38.
- 1281 [84] Liu, H. F., McCooey, B., Duarte, T., Myers, D. E., Hudson, T., Amanullah, A., van  
1282 Reis, R., Kelley, B. D., Exploration of overloaded cation exchange chromatography for  
1283 monoclonal antibody purification. *J. Chromatogr. A* 2011, 1218, 6943–6952.
- 1284 [85] Lee, M. F. X., Chan, E. S., Tam, K. C., Tey, B. T., Thermo-responsive adsorbent for  
1285 size-selective protein adsorption. *J. Chromatogr. A* 2015, 1394, 71–80.
- 1286 [86] Bradford, M. M., A rapid and sensitive method for the quantitation of microgram  
1287 quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.*  
1288 1976, 72, 248–254.
- 1289 [87] Laemmli, U. K., Cleavage of structural proteins during the assembly of the head of  
1290 bacteriophage T4. *Nature* 1970, 227, 680–685.

- 1291 [88] Sigma-Aldrich, Fluorescein Isothiocyanate.
- 1292 [89] Trilisky, E. I., Lenhoff, A. M., Flow-dependent entrapment of large bioparticles in  
1293 porous process media. *Biotechnol. Bioeng.* 2009, 104, 127–133.
- 1294 [90] Yong, C. Y., Yeap, S. K., Goh, Z. H., Ho, K. L., Omar, A. R., Tan, W. S., Induction of  
1295 humoral and cell-mediated immune responses by hepatitis B virus epitope displayed  
1296 on the virus-like particles of prawn nodavirus. *Appl. Environ. Microbiol.* 2015, 81,  
1297 882–889.
- 1298 [91] Kalbfuss, B., Wolff, M., Morenweiser, R., Reichl, U., Purification of cell culture-  
1299 derived Human Influenza A virus by size-exclusion and anion-exchange  
1300 chromatography. *Biotechnol. Bioeng.* 2006, 96, 932–944.
- 1301 [92] Lyddiatt, A., O’Sullivan, D. A., Biochemical recovery and purification of gene therapy  
1302 vectors. *Curr. Opin. Biotechnol.* 1998, 9, 177–185.
- 1303 [93] Lenhoff, A. M., Protein adsorption and transport in polymer-functionalized ion-  
1304 exchangers. *J. Chromatogr. A* 2011, 1218, 8748–8759.
- 1305 [94] Yao, Y., Lenhoff, A. M., Pore size distributions of ion exchangers and relation to  
1306 protein binding capacity. *J. Chromatogr. A* 2006, 1126, 107–119.
- 1307 [95] Biosciences, A., Q Sepharose Fast Flow Product Data. n.d.
- 1308 [96] GE Healthcare, L. S., Q Sepharose High Performance Product Data (Data File 18-  
1309 1172-88 AB). n.d.
- 1310 [97] Bowes, B. D., Koku, H., Czymmek, K. J., Lenhoff, A. M., Protein adsorption and  
1311 transport in dextran-modified ion-exchange media . I : Adsorption. *J. Chromatogr. A*  
1312 2009, 1216, 7774–7784.

1313 [98] Nagase, K., Kobayashi, J., Kikuchi, A., Akiyama, Y., Kanazawa, H., Okano, T.,  
1314 Effects of graft densities and chain lengths on separation of bioactive compounds by  
1315 nanolayered thermoresponsive polymer brush surfaces. *Langmuir* 2008, 24, 511–7.  
1316